

12-2012

Characterization Of Selective Inhibition Of Adenylyl Cyclase Activity By Small Molecule Inhibitor Nky80

Cameron S. Brand

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations



Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Brand, Cameron S., "Characterization Of Selective Inhibition Of Adenylyl Cyclase Activity By Small Molecule Inhibitor Nky80" (2012). *Dissertations and Theses (Open Access)*. 323.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/323

This Thesis (MS) is brought to you for free and open access by the MD Anderson UTHealth Houston Graduate School at DigitalCommons@TMC. It has been accepted for inclusion in Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact digcommons@library.tmc.edu.

**CHARACTERIZATION OF SELECTIVE INHIBITION OF ADENYLYL CYCLASE
ACTIVITY BY SMALL MOLECULE INHIBITOR NKY80**

by

Cameron S. Brand, B.S.

APPROVED:

Carmen Dessauer, PhD
Supervisory Committee Chair

Jeffrey Frost, PhD

Richard Clark, PhD

Alemayehu Gorfe, PhD

John McMurray, PhD

APPROVED:

Dean, The University of Texas
Graduate School of Biomedical Sciences at Houston

**CHARACTERIZATION OF SELECTIVE INHIBITION OF ADENYLYL CYCLASE
ACTIVITY BY SMALL MOLECULE INHIBITOR NKY80**

A
THESIS

Presented to the Faculty of
The University of Texas
Health Science Center at Houston
and
The University of Texas
MD Anderson Cancer Center
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of
MASTER OF SCIENCE

by
Cameron Servetus Brand, B.S.

Houston, Texas

December 2012

Acknowledgements

I would like to thank Dr. Carmen Dessauer for her invaluable mentorship. My adjustment at a young age from undergraduate student to graduate researcher was trickier than it is for most, and I cannot express enough gratitude for the expert advice and direction that has been given.

I also would like to thank the faculty who served on committees. Dr. Terry Walters, Dr. Zhizhong Pan, Dr. Andy Bean, Dr. Alex Gorfe, and Dr. John McMurray are all greatly appreciated for their critiques and advice. Particularly with regards to “seeing the big picture”, Dr. Richard Clark and Dr. Jeff Frost deserve special mention for, along with Dr. Dessauer, sitting as members on my committees and giving feedback on my projects during inter-lab meetings and spur-of-the-moment conversations.

Fellow members of the Dessauer Lab both past and present also deserve recognition. Kathryn Hassell was of great help in getting acclimated to the lab. Dr. Riad Efendi and Dr. Yong Li have been good friends and role models as researchers.

There are too many CRB members of both past and present to list here, but they and the program in general have my profound thanks. My fellow CRB students have been a fantastic support system, and I simply could not have completed this thesis without all of them for practice talks, throwing research ideas back and forth, etc.

Lastly, I would like to thank my parents, Anita and Gary Brand. For 24 years, they have raised, taught, and encouraged me, and have served as a grounding and constant source of support.

CHARACTERIZATION OF SELECTIVE INHIBITION OF ADENYLYL CYCLASE
ACTIVITY BY SMALL MOLECULE INHIBITOR NKY80

Publication No. _____

Cameron Servetus Brand, Ph.D.

Supervisory Professor: Carmen W. Dessauer, Ph.D.

The nine membrane-bound isoforms of adenylyl cyclase (AC), via synthesis of the signaling molecule cyclic AMP (cAMP), are involved in many isoform specific physiological functions. Decreasing AC5 activity has been shown to have potential therapeutic benefit, including reduced stress on the heart, pain relief, and attenuation of morphine dependence and withdrawal behaviors. However, AC structure is well conserved, and there are currently no isoform selective AC inhibitors in clinical use.

P-site inhibitors inhibit AC directly at the catalytic site, but with an uncompetitive or noncompetitive mechanism. Due to this mechanism and nanomolar potency in cell-free systems, attempts at ligand-based drug design of novel AC inhibitors frequently use P-site inhibitors as a starting template. One small molecule inhibitor designed through this process, NKY80, is described as an AC5 selective inhibitor with low micromolar potency *in vitro*. P-site inhibitors reveal important ligand binding “pockets” in the AC catalytic site, but specific interactions that give NKY80 selectivity are unclear. Identifying and characterizing unique interactions between NKY80 and AC isoforms would significantly aid the development of isoform selective AC inhibitors. I hypothesized that NKY80’s selective inhibition is conferred by AC isoform specific interactions with the compound within the catalytic site.

A structure-based virtual screen of the AC catalytic site was used to identify novel small molecule AC inhibitors. Identified novel inhibitors are isoform selective, supporting the catalytic site as a region capable of more potent isoform selective inhibition. Although NKY80 is touted commercially as an AC5 selective inhibitor, its characterization suggests strong inhibition of both AC5 and the closely related AC6. NKY80 was also virtually docked to AC to determine how NKY80 binds to the catalytic site. My results show a difference between NKY80 binding and the conformation of classic P-site inhibitors. The selectivity and notable differences in NKY80 binding to the AC catalytic site suggest a catalytic subregion more flexible in AC5 and AC6 that can be targeted by selective small molecule inhibitors.

Lay Abstract

Adenylyl cyclase (AC) is a protein that produces the signaling molecule cyclic AMP (cAMP). There are nine AC isoforms at cell membranes that, despite being structurally similar and found in various tissue types, have many isoform specific physiological roles. AC5 activity, for example, has been implicated in pain sensation, effects of morphine and other opioids, and heart function. This makes AC5 inhibition desirable as a potential treatment to block chronic pain, lessen the dependence and withdrawal effects of opioids, or protect against chronic heart failure. However, isoform specific inhibition would be important for AC inhibiting drugs in order to limit the number of potential side effects.

There are AC inhibitors used in research that are not suitable for drug development because they are not potent enough, specific enough, and/or are unable to enter cells. This project aimed to characterize isoform selective AC inhibition with a known isoform selective inhibitor and predict how it binds to the catalytic site of AC differently from nonselective inhibitors. Novel AC inhibitors with some isoform selectivity were identified in a virtual screen predicting the binding of small drug-like molecules to the AC catalytic site. Additionally, although being commercially sold as an AC5 specific inhibitor, the small molecule NKY80 was shown to inhibit AC5 as well as the closely related AC6 more potently than the other seven isoforms. Virtual binding of NKY80 to AC predicted that NKY80 has a unique interaction within catalytic site that classical nonselective AC inhibitors do not have so consistently. We propose this region is more flexible in AC5 and AC6, explaining NKY80's selectivity and allowing for targeting of this region to develop more selective AC inhibitors.

Table of Contents

Approval Page	i
Title Page	ii
Acknowledgements	iii
Abstract	iv
Lay Abstract	vi
Table of Contents	vii
List of Illustrations	x
List of Tables	xi
Abbreviations	xii
Chapter 1: Introduction	1
Adenylyl Cyclase Function and Structure	2
AC Regulation	2
AC Roles in Physiology	4
History of AC Inhibitors	8
Significance of Proposed Research	12
Chapter 2: Materials and Methods	13
Virtual Ligand Docking	14
AC Sequence Alignment	15
Cell Line Maintenance	15
Sf9 AC Expression	16
Sf9 Membrane Preparation	16
HEK AC Transfection	17

HEK Membrane Preparation	17
Adenylyl Cyclase Activity Assays	18
Chapter 3: Virtual Docking of AC Catalytic Site	19
Derivation of AC Docking Target	20
Validation of Docking to AC Target	22
Docking of P-Site Inhibitors to AC Target	23
Summary	24
Chapter 4: Screening for Novel Inhibitors at AC Catalytic Site	26
Current Progress on Small Molecule AC Inhibitor Development	27
High Throughput Virtual Screening for Novel AC Inhibitors	28
Screening Candidates for Ability to Inhibit AC	28
Characterizing Selectivity of Novel AC Inhibitors	29
Summary	31
Chapter 5: NKY80 Docking and Full Characterization of AC Isoform Selectivity	35
History of NKY80 Inhibitor	36
NKY80 Docking to AC	36
Comparison of NKY80 Inhibition of AC5 and AC6	37
NKY80 Inhibition Curves for AC 1-9	39
Summary	39
Chapter 6: Discussion	42
AC Isoform Groups and NKY80 Selectivity	43
AC Catalytic Site Residues and Inhibitor Selectivity	44
Chemical Groups Important for NKY80 Inhibition of AC	47

Comparison of NKY80 to Other AC Inhibitors	48
Cardiac Complexes of AC5/AC6 and Inhibitor Selectivity	50
Future Directions	52
Summary	53
Bibliography	54
Vita	72

List of Illustrations

Chapter 1

Figure 1: Schematic of AC Structure.....	3
Figure 2: Notable Small Molecule AC Inhibitors.....	10

Chapter 3

Figure 3: Alignment of Catalytic Site of Crystal AC Structure and Human AC5..	21
Figure 4: Replication of Binding Conformation of 2',3'-dd-ATP.....	22
Figure 5: P-Site Inhibitors Accurately Docked to Catalytic Site.....	25

Chapter 4

Figure 6: Histogram of Top 10% of Scores for ChemBridge Drug-Like Small Molecules..	29
Figure 7: Predicted Binding Conformation and Characterized Isoform Selectivity of Novel AC Inhibitor CB-6673567.....	32
Figure 8: Predicted Binding Conformation and Characterized Isoform Selectivity of Novel AC Inhibitor CB-7833407.....	33
Figure 9: Predicted Binding Conformation and Characterized Isoform Selectivity of Novel AC Inhibitor CB-7921220.....	34

Chapter 5

Figure 10: Predicted Binding Conformation of NKY80..	38
Figure 11: Full AC Isoform Selectivity Characterization of NKY80.....	40

Chapter 6

Figure 12: Structural Flexibility in the AC Catalytic Site.	46
--	----

List of Tables

Chapter 1

Table 1: AC Isoform Expression and Function..... 5

Chapter 5

Table 2: Predicted and Experimental IC₅₀ for NKY80 Inhibition of Adenylyl Cyclase. 41

Abbreviations

AC	Adenylyl Cyclase
ADP	Adenosine Diphosphate
AKAP	A-Kinase Anchoring Protein
ATP	Adenosine Triphosphate
BLAST	Basic Local Alignment Search Tool
C1	Cytosolic Domain 1
C2	Cytosolic Domain 2
cAMP	Cyclic Adenosine Monophosphate
Cl	Chlorine
DMEM	Dulbecco's Modified Eagle Medium
DNA	Deoxyribonucleic Acid
DTT	Dithiothreitol
EDTA	Ethylenediaminetetraacetic Acid
FBS	Fetal Bovine Serum
Fsk	Forskolin
G $\beta\gamma$	Heterotrimeric G Protein Beta-Gamma Subunit
GDP	Guanosine Diphosphate
G α	Heterotrimeric G Protein Inhibitory Alpha Subunit
GPCR	G Protein Coupled Receptor
G α	Heterotrimeric G Protein Olfactory Alpha Subunit
G α	Heterotrimeric G Protein Stimulatory Alpha Subunit
HEK	Human Embryonic Kidney

HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic Acid
MANT	Methylantraniloyl
Mg	Magnesium
Na	Sodium
NT	Amino Terminus
PBS	Phosphate Buffered Saline
PDB	Protein Data Bank
PKA	Protein Kinase A
PKC	Protein Kinase C
PSI	Pounds per Square Inch
sAC	Soluble Adenylyl Cyclase
SDS	Sodium Dodecyl Sulfate
Sf9	<i>Spodoptera frugiperda</i> (clonal isolate)
VMD	Visual Molecular Dynamics

Chapter 1

Introduction

Adenylyl Cyclase Function and Structure

The primary function of adenylyl cyclase (AC) is to produce the signaling molecule cyclic AMP (cAMP), an important 2nd messenger in cell signaling[1]. Production of cAMP occurs through conversion of the cellular energy storage molecule adenosine triphosphate (ATP) into cAMP and pyrophosphate, with cAMP then being free to target downstream signaling proteins. There are nine mammalian membrane-bound isoforms of AC (AC1-9), as well as a soluble mammalian form (sAC). This sAC is similar to the bacterial cyclase predecessor of mammalian AC[2].

Global structure of the membrane-bound AC isoforms is well conserved. Basic organization involves a cytosolic N-terminus (NT) and two other cytosolic domains (C1 and C2) separated by a pair of 6-transmembrane helices[3](Figure 1). The NT domain has sequence and length that varies widely amongst the isoforms. The NT variability allows for some mechanisms of isoform specific regulation. This includes scaffolding actions that may facilitate signal transduction. For example, it has been shown that the AC5 NT anchors heterotrimeric G proteins[4]. The two C1/C2 cytoplasmic domains are 40% similar in sequence, pseudosymmetrical, and form the catalytic area where ATP binds and synthesis of cAMP takes place[5]. These C1/C2 domains are also where various intracellular regulators such as heterotrimeric G proteins interact with AC[6, 7].

AC Regulation

Signaling proteins that similarly regulate all AC isoforms are rare; one notable exception is the heterotrimeric G protein subunit G α , which stimulates all AC isoforms[8-10]. AC isoform specific function is due to differences in tissue expression patterns (Table 1),




Figure 1: Schematic of AC Structure.

regulation, and organization of signaling by scaffolds such as A-kinase anchoring proteins (AKAPs). Some notable differences in regulation allow for organization of AC1-9 into groups. AC 1, 3, and 8 are noted for their stimulation by calcium-stimulated calmodulin; AC 2, 4, and 7 are characterized by considerable conditional stimulation by $G\beta\gamma$; AC 5 and 6 both have sensitive, micromolar level inhibition by free calcium; and AC9 is in a unique class by itself, including insensitivity to the AC activator forskolin[11]. Since C1 and C2 AC domains form the ATP binding site where cAMP production takes place, most regulators of AC directly or indirectly modify this catalytic cleft in order to modulate AC activity. The same signaling protein can also regulate AC isoforms differentially; for example, $G\beta\gamma$ stimulates AC 2/4/5/6/7, but inhibits AC 1/3/8[12, 13].

Metal ions such as Mn^{2+} , Ca^{2+} , and Mg^{2+} also have significant effects at the catalytic site on cAMP production[14]. AC catalyzes phosphoryl transfer by a metal ion mechanism involving Mn^{2+} or Mg^{2+} . This metal requirement is similar to that for DNA polymerase function. Conversely, Ca^{2+} and Zn^{2+} can inhibit AC[15, 16].

Forskolin is a diterpene derived from the root of the plant *Coleus forskohlii*[17]. It is able to clearly stimulate activity of all the membrane-bound AC isoforms except AC9[11, 18]. A single forskolin molecule binds at the interface of the C1 and C2 domains[19]. Due to the C1/C2 pseudosymmetrical structure, the forskolin binding pocket is structurally related to the ATP-binding active site. AC9 is missing a key residue within this forskolin-binding pocket that when mutated can elevate forskolin sensitivity to the level exhibited by the other AC isoforms[20]. Gs α and forskolin are also capable of simultaneous stimulation of AC; whether this stimulation is synergistic or additive is isoform specific[18].

AC5 and 6 are very closely related AC isoforms. They are both stimulated by Gs α and G $\beta\gamma$ [12] and inhibited by Ca²⁺[21] and PKA[22]. Neither is directly inhibited by Go α , although it has been shown that there is a mechanism of indirect inhibition of AC5 or AC6 by Go α signaling that could be blocked by antibodies targeting Go α [23]. The known differences between regulation of AC5 and AC6 are typically subtle. For example, Gs α stimulated activity of either isoform is inhibited by Gi α , but basal activity of AC5 is also inhibited by Gi α while AC6 basal activity is not[24]. Also, AC5 is stimulated by PKC- α and - ζ [25], while AC6 is inhibited by PKC- δ and - ϵ [26, 27]. Gq α signaling can enhance AC6 activity, but not that of AC5, within intact cells by a calcium/calmodulin dependent mechanism[28]. Both isoforms thus have numerous stimulatory and inhibitory inputs to control cAMP levels.

AC Roles in Physiology

The various AC isoforms are involved in many physiological phenomena, with isoform specific roles that are sometimes unclear. Physiological roles of AC cannot solely be explained by tissue distribution. Each AC isoform has a unique tissue expression pattern, but multiple

isoforms are found in nearly all cell types[29]. Originally, the AC/cAMP pathway was characterized by its role in glycolysis and glucose metabolism[30]. Over time, other physiological roles have been identified as well; reviews have been produced that catalogue evidence for various isoform specific functions[6], while a somewhat briefer summary will be given here (Table 1). Learning, memory, and synaptic plasticity involve the closely related isoforms AC1 and AC8[31-36]. AC2, AC4, and AC7 have few clear physiological roles at this point, although evidence suggests AC7's involvement in ethanol dependency[37] and immune cell function[38]. AC3 is involved in olfactory function[39, 40], as well as regulation of renal filtration[41]. AC3 and sAC both appear to have roles in the testes for sperm production and function[42-44]. AC9 has suggested roles in ion channel mediated repolarization of the heart[45] and immune cell migration[46].

Of the AC isoforms, AC5 has by far the widest variety of identified physiological functions, typically being described by AC5 knockout mouse models. AC1 and AC5 have been implicated in different aspects of pain response, with AC5 mouse knockouts having attenuated responses to both mechanical and inflammatory pain[47]. These mice are characterized by limited mechanical and thermal response to normal stimuli in neuropathic pain models. Conversely, pharmacological stimulation of the AC/cAMP pathway increased sensitivity to the inflammatory pain response[48]. AC5 also has been shown, along with AC1, AC6, and AC8, to have an ability for sensitized stimulation. Sensitized stimulation of AC5 occurs through receptor-coupled G α stimulation following prolonged inhibition by receptor-coupled G $\beta\gamma$ protein. Such sensitized activation has been shown with prolonged stimulation of various G $\beta\gamma$ -coupled GPCRs, including D2 dopamine and μ -opioid receptors[49-52]. Tolerance, reward and physiological dependence, and withdrawal symptoms of the opiates are functions where these

Table 1: AC Isoform Expression and Function			
AC Isoform	Tissues With High Expression	Other Tissues Expressed In	Physiological Roles Identified
AC1	Brain	Adrenal Medulla	Learning, Memory, Synaptic Plasticity, Opiate Withdrawal Symptoms
AC2	Brain, Skeletal Muscle	Heart, Lung	Unknown
AC3	Olfactory Bulb	Brain, Heart, Kidney, Lung, Germinal Testis, Brown Adipose	Olfaction, Sperm Function, Renal Filtration
AC4	N/A	Brain, Heart, Kidney, Liver, Lung, Brown Adipose	Unknown
AC5	Heart, Striatum, Adrenal	Brain, Kidney, Liver, Lung, Testis, Brown Adipose	Cardiac Contraction, Aging/Stress Protection, Opiate Dependency/Withdrawal Symptoms, Pain Responses, Motor Coordination
AC6	Brain, Heart, Kidney, Liver, Lung, Adrenal	Testis, Skeletal Muscle, Brown Adipose	Cardiac Contraction, Calcium Sensitivity
AC7	Skeletal Muscle	Brain, Heart, Kidney, Liver, Lung, Testis	Ethanol Dependency, Immune Cell Function
AC8	Brain, Lung	Heart, Testis, Adrenal	Learning, Memory, Synaptic Plasticity, Opiate Withdrawal Symptoms
AC9	Brain, Lung, Skeletal Muscle	Heart, Kidney, Liver, Adrenal, Brown Adipose	Cardiac Repolarization, Immune Cell Migration

receptors have been strongly suggested to play roles. For AC5, this sensitized stimulation appears to also be involved in opiate dependency and withdrawal behaviors, as the effects of morphine were attenuated in AC5 knockout mice[53]. AC5 has also been shown to be involved in motor coordination, with AC5 mouse knockouts developing Parkinson's-like tremors and other motor dysfunctions[54]. All three of these physiological functions are regulated to some degree in the brain by the striatum, where AC5 expression is strongly enriched and is the principal signaling node for D1 and D2 dopamine receptors[55].

Additionally, although multiple AC isoforms are expressed in the heart, AC5 and AC6 are most predominantly expressed[56] and have the most clearly demonstrated cardiac functions at this time. A role of the AC/cAMP signaling pathway in heart failure has been established by models of increased expression of signaling proteins upstream and downstream of AC resulting in cardiomyopathy[57-59]. The primary treatment of choice for individuals that are at high risk for chronic heart failure is β -blockers, consistent with significant involvement of cAMP signaling pathways in cardiac dysfunction[60].

Both AC5 and AC6 are expressed equally in the neonatal heart but AC5 is dominant in the adult heart[61]. Other work has shown AC5 expression mainly in the ventricle while AC6 was in both the ventricle and atria[62]. Thus, it is likely AC5 and AC6 roles in cardiac contraction differ. Disruption of AC5 under thoracic banding simulated stress conditions is protective against heart failure[63]. However, the critical functions of AC5 in the heart are murky as both sympathetic and parasympathetic cardiac regulations are affected in AC5 knockout mice[64]. This includes a complete loss of acetylcholine-mediated $G_{i\alpha}$ inhibition and a significant reduction in Ca^{2+} -mediated inhibition of cAMP production consistent with reduced effects of muscarinic signaling. AC5 loss also desensitizes cardiomyocytes to catecholamine stress, preventing cardiac apoptosis that would otherwise result[65]. This apoptotic reduction may underlie the reduced cardiac stress following aortic banding in knockout mice[63]. AC5 knockout mice also have an increased lifespan and are protected against age-induced cardiomyopathy[66]. This phenotype includes cardiac hypertrophy, apoptosis, and reduced function. Some mouse models for AC5 loss also show increased basal left ventricular function, but decreased responsiveness to beta-adrenergic stimulation that suggests a higher threshold for increasing cAMP signaling over basal levels[67].

History of AC Inhibitors

With all of these physiological functions associated with the AC/cAMP signaling pathway, it is not surprising that the pathway is an attractive target for drugs to modulate these functions. As a result, many drugs have been identified that target cAMP signaling[68]. Salmeterol is a partial agonist of the β 2-adrenergic receptor, increasing cAMP production to increase circulation useful in the treatment of asthma. Theophylline is a phosphodiesterase inhibitor and adenosine receptor antagonist also used as an asthmatic treatment by maintaining elevated cAMP, albeit as a less frequently used treatment. Beta-blockers decrease cAMP and are used as treatments for various heart conditions, such as metoprolol for hypertension and heart failure. Morphine is a μ -opioid receptor agonist that decreases cAMP and, in turn, inhibits pain sensation. Various dopamine receptor agonists and antagonists modulate cAMP activity downstream as therapeutics for schizophrenia, Parkinson's disease, and nausea.

However, these therapeutics target upstream GPCRs or downstream regulators of cAMP concentration. Direct control of cAMP production by targeting AC activity has been a more difficult target. The structural similarity and overlapping tissue expression of AC isoforms provide great risk for nonspecific effects. Since AC is an enzymatic protein with transmembrane and cytoplasmic domains, the lack of extracellular domains such as those targeted by ligands on GPCRs mean an AC drug must be capable of passing through the plasma membrane, which has severely limited the kind of molecules that progress past cell-based systems and preclinical animal models. Some AC inhibitor prodrug packages have been attempted to circumvent this issue[69, 70]. However, the current state is that there are no isoform specific AC inhibitors in clinical use.

That being said, there has been progress in identifying AC isoforms that would be desirable as targets if they could be selectively inhibited. Since it has been shown that AC5, AC1, and AC8 are involved in inflammatory/neuropathic pain, but only AC5 does not cause any major defects in knockout mouse models, AC5 inhibitors have promise as analgesics. Since negative side effects due to compensatory mechanisms are induced by long-term opioid use in patients with chronic pain, AC5 selective inhibitors for patients could also be more viable for long-term treatment. Based on AC5 knockout models, AC5 inhibitors could also act similarly to beta-blockers in the treatment of heart failure. The predominant expression of AC5 and closely related AC6 in heart failure combined with their differing effects on cardiac function requires a selective ligand that would inhibit AC5 but not AC6. The drastic AC5 activity differences in chronic versus acute heart failure also has to be taken into account for prospective drug development. It has been suggested that increased cAMP from AC5 activity is beneficial as a rescue function in acute heart failure, but is clearly detrimental in chronic failure models. Colforsin daropate hydrochloride is a direct activator of AC5 (with AC6 potency unknown)[71]. Its effects include coronary vasodilation[72], and the activator is an approved treatment in Japan for acute heart failure[73].

In research, two distinct classes of small molecule AC inhibitor are commonly among those utilized. Examples of these inhibitor classes and some notable inhibitors derived from them are shown in Figure 2. One of these classes is P-site inhibitors, which bind in the AC catalytic site and decrease activity through uncompetitive inhibition[74, 75]. The original P-site inhibitors, which we will call classic P-site inhibitors, are adenosine nucleotide analogs with a phosphate or polyphosphate group at the 3' position of a ribose ring. These inhibitors are more potent on activated forms of AC versus the basal state, forming a product-like transition state




Figure 2: Notable Small Molecule AC Inhibitors.

with pyrophosphate to prevent further ATP binding[76]. Although most of the classic P-site inhibitors were synthetically made, some are naturally occurring variants of ADP and ATP[77]. More potent inhibitors, such as adenosine 3'-polyphosphates (i.e. 2',5'-dideoxy-3'-ATP), bind in the absence of pyrophosphate with the aid of the 3'-phosphates, increasing the affinity of these

inhibitors by 100- to 1,000-fold[78, 79]. This conformation is also produced by the noncompetitive ATP analog 2',3'-dideoxy-5'-ATP, currently the most potent AC inhibitor at a K_i of 16nM for rat brain AC[80]. Although most classic P-site inhibitors lack isoform selectivity, there are some exceptions. It has been shown that 2'-deoxy-3'-AMP is mildly selective for AC1 over AC2 and AC6[81]. Also, AC9 is insensitive to 2'-deoxy-3'-AMP [81]. In general, however, P-site inhibitors that are not products of inhibitor optimization experiments are not greatly selective against certain isoforms. P-site based inhibitors nonetheless are extremely direct and potent inhibitors; these compounds typically have affinities of nanomolar concentration.

The other predominant class of direct small molecule AC inhibitors is the MANT-nucleotide inhibitors. One such example is MANT-GTP, which has a K_i of 53nM in Sf9 cyc-lymphoma cell membranes[82]. MANT-GTP binds in the ATP-binding site with a nucleotide in reverse orientation compared to ATP analogs such as P-site inhibitors[83, 84]. Interestingly, published research suggests that MANT-GTP and similar MANT-nucleotides show potential for designing isoform selective compounds that target the AC catalytic site despite the structural similarity of AC isoforms[83, 85]. These MANT-GTP screens suggested inhibitor affinity was more dependent on the ribose and polyphosphate components of such small molecule AC inhibitors, not necessarily the base component. Thus, non-nucleotide based inhibitors able to modulate AC activity directly at the catalytic site are theoretically possible at therapeutically desirable potency levels. The crystal structure of MANT-GTP with AC also suggests catalytic site flexibility, with the movement of helices to accommodate the MANT group in a "C" pocket that can accommodate hydrophobic interactions. Crystallized P-site inhibitors show only two subregions of the ATP binding site; an "A" pocket where hydrogen

bonding to the purine group takes place, and a “B” pocket including the two metal ion binding sites and typically containing metal-phosphate interactions. MANT-GTP γ S introduced into whole-cell mouse cardiomyocytes by patch pipette has been used to attenuate L-type calcium channel currents that was presumably through inhibition of coupled AC5[86].

Significance of Proposed Research

Validation of isoform selective small molecule AC inhibitors in preclinical animal models is a stage of therapeutic development rarely reached. The most significant obstacle is generating small molecule inhibitors with sufficient potency, selectivity, and therapeutic potential combined. One small molecule inhibitor that resulted from searching for these characteristics in a compound derived from P-site inhibitors, NKY80, is described as an AC5 selective inhibitor with low micromolar potency *in vitro*. Classic small molecule AC inhibitors have revealed important ligand-binding “pockets” in the AC catalytic site, but what specific interactions in these regions give NKY80 selectivity is currently unclear.

Identifying and characterizing unique interactions between NKY80 and AC isoforms could be used to determine isoform specific differences in the interaction of the well conserved catalytic site with regulatory molecules, and as a result significantly aid the development of isoform selective AC inhibitors with therapeutic potential. I hypothesize that unique isoform specific interactions between the AC catalytic site and NKY80 explain the small molecule’s selective inhibition profile.

Chapter 2

Materials and Methods

Virtual Ligand Docking

Searching for novel directly binding AC inhibitors was performed by using Glide docking software from Schrödinger to dock ligands specifically to the catalytic ATP binding site of AC. Both known P-site inhibitors and 35,000 compounds from the generic ChemBridge library of drug-like small molecules that follow Lipinski's rule of five were used as ligand libraries. These libraries were docked to a model of the AC catalytic site adapted from crystal structure of the AC C1/C2 domains bound with the inhibitor 2',3'-dd-ATP (PDB ID 1CJT)[16]. This model had waters, forskolin, Gas protein, Mg²⁺ ion, Cl⁻ ion, and buffer molecules removed, leaving only the AC C1 and C2 domains. Ligand 3D structures were prepared, including unprotonated state and creation of stereoisomers, using Schrödinger's LigPrep software. Docking was restricted to the ATP binding region of the catalytic cleft. Hydrogen bonds were defined by a donor-acceptor distance cutoff of 3.5 Å and a donor-hydrogen-acceptor angle between 150° and 180°. ChemBridge ligands were ranked based on the Glide predicted energy score in kcal/mol and most energetically favorable binding pose.

AutoDock 4.2 was used to dock known P-site inhibitors and NKY80 to the entire structure of the AC catalytic site model from crystal structure 1CJT. Docking to the entire AC structure was chosen to test if AutoDock correctly predicts P-site inhibitor binding to the catalytic site in an unbiased manner, as well as to provide a comprehensive prediction of the NKY80 binding site. The value of such a "blind docking" procedure has been demonstrated previously[87]. Briefly, small molecule inhibitor ligands were prepared with AutoDock tools, creating a nonpolar atomic charge sum and calculating the Gasteiger charges and torsions[88, 89]. AutoDock 4.2 was then used to dock the ligands onto a grid large enough to encompass the entire surface of the AC catalytic site from crystal structure 1CJT with 0.375 Å grid spacing. A

population size of 150, with 2 Å clustering cutoff, 10,000 LGA hybrid with 256 runs was used. Predicted poses were analyzed in terms of their energetic binding potential. Hydrogen bonds were defined as described for Glide docking. Van der Waals contacts were defined by a carbon-carbon distance cutoff of 5.0 Å. Potential poses were predicted and ranked based on the predicted binding affinities.

The free ICM-Browser available from Molsoft L.L.C. was used to visually inspect predicted conformations of ChemBridge small molecules during virtual screening. In addition, VMD Viewer 1.9 from the Theoretical and Computational Biophysics Group at the University of Illinois at Urbana-Champaign was used for visual analysis of the known inhibitor docking results, and for image rendering.

AC Sequence Alignment

Alignment of two or more AC sequences using BLAST (<http://blast.ncbi.nlm.nih.gov/>) was utilized to compare C1 and C2 domains of various AC isoforms. The primary sequences of the C1/C2 domains used in a crystallized AC structure (PDB ID 1CJT) were aligned with the corresponding C1/C2 sequences of human AC1-9.

Cell Line Maintenance

Sf9 insect cells were maintained with SF-900 II SFM media contained in cell suspension flasks. Cells were passaged to maintain a concentration of log phase cells between 0.5×10^6 and 5.5×10^6 cells/ml. Cell incubation was in a 27°C shaker at 150rpm.

HEK293 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum and 1% penicillin/streptomycin on 10cm dishes in a 37°C, 5% CO₂ incubator.

Sf9 AC Expression

Baculoviruses were amplified for 5-7 days using 500µl of storage virus stock with 50ml of Sf9 cells in log phase in SF-900 II SFM media with 50 µg/ml gentamicin at a concentration of 1.5-2 X 10⁶ cells/ml to produce a baculovirus working stock with a minimum titer of 1 X 10⁷ pfu/ml. 25ml of the appropriate AC isoform baculovirus was used to infect 1 liter of Sf9 cells at a concentration of 1.5-2 X 10⁶ cells/ml. After 48 hours of infection, Sf9 cells were harvested by centrifugation at 1000 g for 10 minutes at 4°C.

Sf9 Membrane Preparation

Harvested cells were suspended in 600ml of cold lysis buffer consisting of 50 mM NaHEPES (pH 8.0), 0.1 mM EDTA, 3 mM MgCl₂, 10 mM β-mercaptoethanol, 100 mM NaCl, 10 µM GDP, 0.02 mg/ml phenylmethylsulfonyl fluoride, 0.03 mg/ml leupeptin, 0.02 mg/ml 1-chloro-3-tosylamido-7-amino-2-heptanone, 0.02 mg/ml L-1-tosylamido-2-phenylethyl chloromethyl ketone, and 0.03 mg/ml lima bean trypsin inhibitor. Cells were lysed by nitrogen cavitation at 500 PSI, 4°C for 30 min. Cell lysates were centrifuged at 750g for 10 min at 4°C to remove intact cells and nuclei. The supernatants were centrifuged at 100,000g for 30 min at 4°C. Resulting pellets were suspended in 300 ml of buffer consisting of 50 mM NaHEPES (pH 8.0), 3 mM MgCl₂, 10 mM β-mercaptoethanol, 50 mM NaCl, 10 µM GDP, and proteinase inhibitors as above, dounce homogenized, and centrifuged again at 100,000g for 30 min at 4°C.

Resulting pellets were then resuspended. Resuspended Sf9 membrane pellets had concentration determined by Bradford assay, with membranes then immediately frozen in liquid nitrogen and stored at -80°C in one-use aliquots for future adenylyl cyclase activity assays (see below).

HEK AC Transfection

HEK293 cells were seeded at 3×10^6 cells per 10cm dish in DMEM with 10% FBS approximately 24 hours before transfection. On the next day, medium was replaced with fresh DMEM (no FBS or penicillin/streptomycin). The appropriate plasmids (10ug DNA total per plate) and Lipofectamine 2000 transfection reaction (3µl per 1ug DNA, or 30µl per plate) were separately incubated in OPTI-MEM medium for 5 minutes, and then in combination for an additional 20 minutes. The transfection solution was then added dropwise to the appropriate cell dishes. Cells were incubated at 37°C for 4-6 hours. The media was then replaced with DMEM + 10% FBS and returned to the incubator. In total, the cells were incubated for approximately 40 hours before harvesting.

HEK Membrane Preparation

Following 40 hour cell transfections (see above), HEK293 cells were rinsed with cold PBS and scraped from 10cm dishes with cold PBS + protease inhibitors. Cells were then pelleted by centrifugation at 3000g, 4°C for 5 minutes. Cell pellets were aspirated and resuspended in 20mM HEPES, 1mM EDTA, 2mM MgCl₂, 1mM DTT, 250mM sucrose, and protease inhibitors. Cells were incubated on ice for 10-30 minutes and then homogenized with a 2ml dounce homogenizer. Cell homogenates were centrifuged at 1800g, at 4°C for 5 minutes to pellet nuclei. The supernatants were transferred to firm-walled microfuge tubes and

centrifuged at 60,000g, 4°C for 20 minutes. The resulting membrane pellet was resuspended in 20mM HEPES, 1mM EDTA, 2mM MgCl₂, 1mM DTT, and 250mM sucrose. HEK membrane concentrations were determined by Bradford assay. Membranes were immediately assayed in adenylyl cyclase activity assays (see below) or frozen in liquid nitrogen and stored at -80°C in one-use aliquots for future assays.

Adenylyl Cyclase Activity Assays

As performed and described previously[90], Sf9 or HEK membrane preparations (see above) were incubated for 10 minutes at 30°C with an AC mix containing $\{\alpha\text{-}^{32}\text{P}\}$ ATP and appropriate activators. The activators used were 50 μ M forskolin for Sf9 membranes of AC1-7, 100 μ M calcium and 300 μ M calmodulin for HEK membranes of AC8, and 300nM Gs α for HEK membranes of AC9. Reactions were stopped with a solution of 2.5% SDS, 50mM ATP, and 1.75mM cAMP. Nucleotides in each reaction sample were then separated by column chromatography to isolate $\{^{32}\text{P}\}$ cAMP product produced by AC membranes during the reaction period, using $\{^3\text{H}\}$ cAMP to monitor column recovery rates. Separated samples were collected in scintillation vials with scintillation fluid. Production of cAMP was measured by scintillation counting using a dual dpm program to count $\{^3\text{H}\}$ cAMP and $\{^{32}\text{P}\}$ cAMP isolated from each sample.

Chapter 3

Virtual Docking of AC Catalytic Site

Derivation of AC Docking Target

Crystal structures of AC have been obtained from purified C1/C2 catalytic domains of AC, as the N-terminus and membrane-spanning domains are too unstable for crystallization. These purified C1/C2 domains were originally produced to have a soluble, membrane-free setting for characterizing C1/C2 domain interactions with each other and/or AC regulators[91]. In solution, these domains are capable of reproducing conversion of ATP into cAMP[92, 93]. The original crystallization producing an AC structure model used a pair of rat AC2 C2 domains with the activator forskolin[94], but this cytosolic domain combination was catalytically dead. The first active crystallized structure, consisting of canine AC5 C1 and rat AC2 C2 domains, was stable enough to form a crystallized structure with bound activators forskolin and G α [5]. This also clarified the pseudosymmetrical nature of AC catalytic structure, including its mechanism of regulation by heterotrimeric G protein α subunits. Exploration of the method of metal catalysis of AC activity by crystallization of the AC catalytic core followed[16]. These 5C1/2C2/Fsk/G α catalytic structures showed variants of “open” conformations conducive to active AC, but not the inactive “closed” conformations that would be expected to occur with a bound inhibitor. Subsequent crystallization of AC catalytic cores aimed to identify such inactive conformations. Such crystallizations included the conformations of P-site inhibitors binding to the ATP-binding site despite their typically uncompetitive inhibitory mechanism[76], the competitive MANT-nucleotide inhibitors binding at the same site[84, 85], and the binding of free calcium ions to inhibit AC5 and AC6[95].

In order to perform a virtual screen against AC, we used PDB 1CJT, which is an AC structure comprised of 5C1/2C2/Fsk/Gs α co-crystallized with one Mg²⁺ and one Mn²⁺ in the metal ion binding sites, and the ATP analog 2',3'-dideoxy-5'-ATP[16]. Modification of this crystal structure into a computational target began with the removal of all waters and the Gs α protein in order to focus on interactions between ligands and the C1/C2 domains of AC. Two metal ions are typically seen in crystallized structures, but it is questionable that both are required for catalysis; experiments suggest complexes of P-site inhibitors with one metal[96]. Additionally, in terms of computational docking, metal ions are typically a major charge-based energetic demand that is favored over other interactions that may have more importance for ligand-target specificity. Thus, to minimize false positives only binding to the metal ions, only the Mn²⁺ metal that interacts with the γ -phosphate of 2',3'-dd-ATP was kept. The crystal structure in the area within 5 Å of this inhibitor's bound conformation was confirmed by sequence alignment to be identical to human AC5 (Figure 3). This is despite the C2 domain being from AC2, as the catalytic region is so homologous.

```

Human AC5 C1 | 472 FADIEGFTS 480 | 513 KILGDC 518 |
1CJT AC C1 | 395 FADIEGFTS 403 | 436 KILGDC 441 |

Human AC5 C1 | 560 MRV 562 | 594 MEA 596 |
1CJT AC C1 | 483 MRV 485 | 517 MEA 519 |

Human AC5 C2 | 1073 MFA 1075 | 1121 KIKTIG 1126 | 1129 YMA 1131 |
1CJT AC C2 | 888 MFA 890 | 936 KIKTIG 941 | 944 YMA 946 |

Human AC5 C2 | 1196 YDIWGNTVNVASRM 1209 | 1243 VKGK 1246 |
1CJT AC C2 | 1017 YDIWGNTVNVASRM 1030 | 1064 VKGK 1067 |

```

Figure 3: Alignment of Catalytic Site of Crystal AC Structure and Human AC5. Residues within 5 Å of the crystallized conformation of 2',3'-dd-ATP in PDB ID 1CJT are indicated in red.

Validation of Docking to AC Target

It had to be confirmed that it was possible to replicate the known crystal binding position of 2',3'-dd-ATP with the binding position predicted by virtual docking. In order to justify use of the modified version of crystallized AC structure as a computational docking target, 2',3'-dd-ATP was thus redocked with Glide and AutoDock. Results show that the predicted docking pose that was produced for 2',3'-dd-ATP closely replicates the crystallized binding conformation (Figure 4). This demonstrates the ability to replicate the known bound conformation of a small molecule ligand, in this case the inhibitor 2',3'-dd-ATP, through virtual docking.




Figure 4: Replication of Binding Conformation of 2',3'-dd-ATP. (A) Chemical structure of 2',3'-dd-ATP. (B) Overlay of predicted (cyan carbons) and crystallized (grey) binding conformations of 2',3'-dd-ATP by AutoDock 4.2 docking program. AC C1 domain is yellow, AC C2 domain is silver, manganese metal ion is orange.

Docking of P-Site Inhibitors to AC Target

Classic P-site inhibitors all bind to AC similarly, with an adenine or adenine-like group in the “A” pocket, and a multi-phosphate group in the metal-containing “B” pocket. Other crystallized structures of AC C1/C2/Gs α /Fsk with classic P-site inhibitors include the conformations of 2'-deoxy-3'-AMP with pyrophosphate (PDB ID 1CS4) and 2',5'-dideoxy-3'-AMP with triphosphate (PDB ID 1CUL). These P-site inhibitors were previously used in other crystallized structures of AC to explore the mechanism of P-site regulation[76]. It was of interest to determine if the developed AC catalytic site target was capable of producing realistic binding positions for other small molecule inhibitors. Thus, as ligands known to bind to the AC catalytic site but not included in the 1CJT crystallization, these P-site inhibitors were docked to the AC target derived from 1CJT. As mentioned, the 1CS4 and 1CUL crystal structures used pyrophosphate and triphosphate respectively and our docks were with one ligand. Thus we docked 2'-d-AMP without the pyrophosphate molecule, and docked 2'5'-dd-ATP as an estimation of 2',5'-dd-AMP with triphosphate.

Again, the ligand docking produced conformations with adenine-like groups bound to the “A” pocket and phosphates predictably interacting with the manganese ion in the “B” pocket (Figure 5). 2'-d-AMP's highest scoring predicted pose from docking to the 1CJT structure model overlapped significantly with the crystallized pose for 2'-d-AMP and pyrophosphate from 1CS4. The largest deviations were the small molecule's single phosphate attempting to compensate for the missing pyrophosphate's metal interactions. Although the highest scoring pose when docking 2'5'-dd-ATP to the 1CJT-derived model did not have significant overlap with the crystallized conformation from 1CUL (Figure 5D), the P-site

inhibitor was targeted to the ATP-binding area of the catalytic domains. Furthermore, the second highest scored pose did show significant replication of the crystallized position (Figure 5E). The difference in predicted affinity for these two conformations was 0.43 kcal/mol, or approximately 6.13 attomolar. This is a fairly small difference between two predicted conformations; thus, the accurately predicted pose with the second highest score can be considered as a co-highest scored pose. As P-site inhibitors bind similarly, it is worth noting that all three P-site inhibitors tested have overlap in the same binding pockets across crystal structures. Thus, predicted binding conformations of analogs for crystallized P-site inhibitors were able to closely simulate their crystal structure counterparts despite being docked to a slightly different representation of the AC catalytic region, albeit one with little variation. This suggests the computational AC catalytic target developed is useful for docking of any P-site inhibitor like compounds.

Summary

Using the structure of the AC catalytic domains crystallized with the inhibitor 2',3'-dd-ATP (PDB ID 1CJT), a target for computational docking to the ATP-binding region of AC was developed. Redocking of this inhibitor replicated the actual crystallized conformation. Additionally, attempted docking of P-site inhibitors to the same site closely replicated their crystallized positions, supporting the developed AC target as a reliable model of the catalytic site for docking P-site inhibitors and similar compounds.




Figure 5: P-Site Inhibitors Accurately Docked to Catalytic Site. (A) Chemical structure of 2'-d-AMP. (B) Overlay of top scoring predicted conformation of 2'-d-AMP (cyan carbons) and crystallized binding conformation of 2'-d-AMP with pyrophosphate (grey) by AutoDock 4.2 docking program. (C) Chemical structure of 2',5'-dd-AMP. (D) Overlay of top scoring predicted conformation of 2',5'-dd-ATP (cyan carbons) and crystallized binding conformation of 2',5'-dd-AMP with triphosphate (grey) by AutoDock 4.2 docking program. (E) Overlay of second highest scoring predicted conformation of 2',5'-dd-ATP (cyan) and crystallized binding conformation of 2',5'-dd-AMP with triphosphate (grey) by AutoDock 4.2 docking program. For (B), (D), and (E), AC C1 domain is yellow, AC C2 domain is silver, manganese ion is orange.

Chapter 4

Screening for Novel Inhibitors at AC Catalytic Site

Current Progress on Small Molecule AC Inhibitor Development

Due to an uncompetitive or noncompetitive inhibitory mechanism and a nanomolar range of potency in cell-free systems, attempts at ligand-based drug design of novel AC inhibitors have frequently used P-site inhibitors as a starting point. This is despite their typically nonselective inhibition of AC isoforms, providing risk for off-target effects. A main concern regarding P-site inhibitors is the requirement of adenine group and ribose ring[97]. Such a requirement could cause inhibition of enzymes such as DNA polymerases, kinases or ATP synthases[70]. However, small molecule compounds subsequently developed do not necessarily have these chemical groups. A notable group of compounds derived from P-site inhibitors contain an additional metal chelating group and exhibit enhanced AC isoform selectivity, most notably the AC5 selective PMC-6[98-100].

There is also limited development of small molecules that inhibit AC at the C1/C2 catalytic cleft but do not bind in the ATP-binding site pockets. Examples of these are the tyrphostins, catechol oestrogens, and calmidazolium, which like PMC-6 chelate metal ions necessary for catalysis of ATP conversion to cAMP[101, 102].

Only a few *in vivo* studies have been conducted with small molecules developed from classic P-site inhibitors. One success story is HTS09836, a patented AC1 inhibitor and orally available drug. HTS09836 decreases cAMP in human neuronal slices and decreases pain-related behaviors in rat pain models, demonstrating the therapeutic potential of compounds based on P-site inhibitors[103]. As most P-site inhibitors cannot cross cell membranes and/or are degraded by adenosine deaminase in intact cells, HTS09836 is a notable exception to the rule of P-site inhibitors performing poorly in cultured cells or animals.

High Throughput Virtual Screening for Novel AC Inhibitors

The validated AC docking target derived from PDB 1CJT was used to identify novel AC inhibitor candidates that lack the issues for therapeutic development that classic P-site inhibitors do, such as similarity to ATP. Flexible drug-like small molecules from ChemBridge were docked at the ATP binding site of AC in a structure-based virtual screen. The library consisted of approximately 35,000 small drug-like ligands. Higher scoring compounds consistently had interactions in the previously mentioned “A” and “B” pockets of the ATP binding site. As these compounds were from a generic drug-like molecule library, predicted hits rarely had chemical groups resembling adenine in the “A” pocket and never had phosphates in the “B” pocket.

Screening Candidates for Ability to Inhibit AC

A randomly produced list of 300 ligands of the 3500 that scored in the 90th percentile or above was visually inspected for realism of predicted binding conformation and the existence of interactions beyond those between the ligand and Mn²⁺. Based on this subjective inspection and subsequent clustering of the acceptable predicted hits, 58 highly distinct ligands were selected for *in vitro* testing. These compounds were then tested with an AC activity assay to determine their ability to inhibit AC. Of the compounds that were able to inhibit AC5 at a concentration of 1mM, an inhibitor concentration of 100μM was tested against AC1, AC2, AC5, and AC6. Three compounds showed isoform selective inhibition at 100μM; CB-6673567, CB-7833407, and CB-7921220. All of the compounds selected for testing turned out to have scored near or above 99th percentile of the structure-based virtual screen (Figure 6).




Figure 6: Histogram of Top 10% of Scores for ChemBridge Drug-Like Small Molecules. Top 1% of scores to the left of red line. Glide docking scores from the virtual docking screen for ChemBridge small drug-like molecules identified as isoform selective AC inhibitors *in vitro* are indicated by blue arrows.

Characterizing Selectivity of Novel AC Inhibitors

These three novel inhibitors all decreased AC5 activity by at least 50% at a concentration of 1mM (Figures 7B, 8B, 9B). While 1mM is a relatively high concentration for a desirable AC inhibitor, all three compounds had chemical groups not closely related to adenine or triphosphate groups. Additionally, the requirement of a ribose or ribose-like ring was not found in these small molecule inhibitors. With the inhibition of AC5 demonstrated by

these novel molecules, it was then determined whether these inhibitors also had any AC isoform selectivity properties.

CB-6673567 was able to inhibit AC1 much more strongly than the other AC isoforms at 100 μ M (Figure 7). Its binding conformation puts a large number of AC residues in close proximity, but no unique interactions are apparent. CB-6673567 binds in the catalytic cleft, inserting its pyrazole rings to the “A” pocket. However, the placement of its benzene ring in free space where presumably there would be water in a biological setting suggests a slightly different actual conformation for either the inhibitor or the AC structure.

CB-7833407 has a unique binding conformation that makes hydrogen bonds that are typically seen by ligands in the “A” pocket (Figure 8). The ligand structure is not near any AC residues while the other end blocks ATP binding via “A” pocket interactions. This appears to be a shared property of the predicted conformations for CB-6673567 and CB-7833407.

Interactions with AC residues in close proximity to these ligands are not provided outside the “A” pocket despite the presence of large chemical groups for both ligands that are outside this pocket. For CB-7833407, this non-pocket chemical structure includes a chlorine atom.

Regarding inhibitory potential, CB-7833407 has isoform selective inhibition of AC2. Thus, the novel AC isoform inhibitors identified differ in their selectivity profiles.

Lastly, CB-7921220 selectively inhibits AC1 and has a more conventional predicted binding conformation (Figure 9). Hydrogen bonds are formed in the “A” pocket between CB-7921220 and Asp1018 in the as well as Ile1019 of AC. The carboxyl group on the other end of the ligand is stabilized by close proximity to the Mn²⁺ ion in the “B” pocket, and to a lesser extent by a possible interaction with Thr401.

The AC1 and AC2 selective inhibition by these novel small molecules support different binding conformations in the AC catalytic site conferring different isoform selectivity profiles. Comparison of interacting residues with both CB-6673567 (Figure 7D) and CB-7921220 (Figure 9D) shows significant interaction overlap. However, the majority of this overlap is in the “A” pocket where any direct inhibitor must bind, and no residues previously characterized as important for ligand binding are closer than they would be to a typical P-site inhibitor. Thus, there is no novel interaction that clearly is conferring the observed AC1 selectivity to these inhibitors. AC residue Thr401 has an oxygen within 3.08 Å of CB-6673567, and its backbone amide is within 2.89 Å of CB-7921220. Although not yet confirmed, the catalytic site subregion containing Thr401 may provide the AC1 selectivity seen in these molecules. We were able to find isoform selective novel AC inhibitors as predicted, although it is surprising that none of the three had the intended selectivity for AC5 inhibition.

Summary

A large-scale structure-based virtual screen docked small drug-like molecules at the AC catalytic site with Glide. Using this approach, novel small molecule inhibitors from the ChemBridge library of drug-like compounds were identified that have little to no similarity in chemical structure to other known AC inhibitors. Three novel inhibitors identified show varying isoform selective inhibition of AC.




Figure 7: Predicted Binding Conformation and Characterized Isoform Selectivity of Novel AC Inhibitor CB-6673567. (A) Chemical structure of novel AC inhibitor CB-6673567. (B) Isoform selective AC inhibition by CB-6673567. 15μg of membranes of indicated AC isoform stimulated by 50μM forskolin, incubated with indicated concentration of inhibitor. $p < 0.05$ for *, $p < 0.01$ for **, $p < 0.001$ for *. (C) Predicted binding conformation of CB-6673567 (cyan carbons) in AC catalytic site by Glide docking program. C1 domain is yellow, C2 domain is silver, manganese metal ion is orange. (D) Predicted binding conformation of CB-6673567 (cyan carbons) with AC catalytic site residues within 3.5 angstroms displayed (grey carbons).**




Figure 8: Predicted Binding Conformation and Characterized Isoform Selectivity of Novel AC Inhibitor CB-7833407. (A) Chemical structure of novel AC inhibitor CB-7833407. (B) Isoform selective AC inhibition by CB-7833407. 15μg of membranes of indicated AC isoform stimulated by 50μM forskolin, incubated with indicated concentration of inhibitor. $p < 0.05$ for *, $p < 0.01$ for **, $p < 0.001$ for *. (C) Predicted binding conformation of CB-7833407 (cyan carbons) in AC catalytic site by Glide docking program. C1 domain is yellow, C2 domain is silver, manganese metal ion is orange. (D) Predicted binding conformation of CB-7833407 (cyan carbons) with AC catalytic site residues within 3.5 angstroms displayed (grey carbons).**




Figure 9: Predicted Binding Conformation and Characterized Isoform Selectivity of Novel AC Inhibitor CB-7921220. (A) Chemical structure of novel AC inhibitor CB-7921220. (B) Isoform selective AC inhibition by CB-7921220. 15μg of membranes of indicated AC isoform stimulated by 50μM forskolin, incubated with indicated concentration of inhibitor. $p < 0.05$ for *, $p < 0.01$ for **, $p < 0.001$ for *. (C) Predicted binding conformation of CB-7921220 (cyan carbons) in AC catalytic site by Glide docking program. C1 domain is yellow, C2 domain is silver, manganese metal ion is orange. (D) Predicted binding conformation of CB-7921220 (cyan carbons) with AC catalytic site residues within 3.5 angstroms displayed (grey carbons).**

Chapter 5

NKY80 Docking and Full Characterization of AC

Isoform Selectivity

History of NKY80 Inhibitor

Based on the structure of the cell permeable, AC5 selective P-site inhibitor SQ22536, NKY80 was developed in order to produce a similarly selective inhibitor with a structure that did not contain an intact adenine ring. This is due to concern over off-target effects involving inhibition of DNA polymerases, kinases, and ATP synthases. NKY80 maintains an adenine-like motif at the C2 and C6 carbons that was accurately predicted to be essential for AC5 inhibitors[104]. However, the adenine ring in NKY80 is modified elsewhere, eliminating DNA synthesis inhibition as a potential off-target effect. NKY80 shows inhibition for AC5 with a K_i in cell-free assays of $8.3\mu\text{M}$ [104]. This inhibition is more potent compared to the ability of NKY80 to inhibit AC3 (16-fold) and AC2 (200-fold) [104], and thus may serve as a good template for the development of other AC5 inhibitors. Like its P-site inhibitor predecessors, NKY80 is also not a competitive inhibitor[104]. However, while it is derived from a cell permeable AC inhibitor, NKY80 was not effective when tested in a cell-based assay[105]. Reasons for membrane impermeability based on the chemical structure of NKY80 are not apparent. Additionally, its potential for inhibiting isoforms other than AC2, AC3, or AC5 has not been characterized. Regardless, for research NKY80 is currently considered a standard for selective small molecule inhibition of AC5.

NKY80 Docking to AC

Classic P-site inhibitors bind with an adenine group in the “A” pocket, a multi-phosphate group in the metal-containing “B” pocket, and a connecting ribose or ribose-like ring group. This binding position supported in the literature has been replicated as part of validating the computational structure of the AC catalytic site that was developed as a docking target for

small molecule AC inhibitors. NKY80 is an optimized small molecule inhibitor originally derived from the structure of a P-site inhibitor, and has been shown previously to have a selectivity characteristic that classic P-site inhibitors do not have. In order to determine the AC structural interactions that could explain this unique selectivity, NKY80 was docked to the AC structure with AutoDock (Figure 10). The adenine-modified chemical group of NKY80 bound to the “A” pocket. However, NKY80 has no phosphates to interact with metal ions in the “B” pocket as shown by P-site inhibitors, either directly or indirectly with pyrophosphate. The clearest difference of NKY80 to 2',3'-dd-ATP is in the ring region between the “A” and “B” pockets. 2',3'-dd-ATP has a ribose ring that, while having some potential for intermolecular interaction, more notably serves as a connector between high affinity phosphate-metal interactions and “A” pocket interactions that block off the binding region for an adenine base. The furan ring of NKY80 instead shows a substantial shift towards Asn1025 on the C2 domain of AC. This shift brings a likely potential hydrogen bond between NKY80 and Asn1025 within a bond distance of 2.9 Å. Although its sole importance cannot be verified by this method, this result does suggest a strong role for Asn1025 in AC inhibition by NKY80. It is unclear if this interaction explains the selectivity profile of NKY80, or how it is able to inhibit at the catalytic pocket at nanomolar concentrations despite lacking a phosphate or polyphosphate group.

Comparison of NKY80 Inhibition of AC5 and AC6

In previous NKY80 characterizations, NKY80 had its inhibition potency for AC5 compared to AC2 and AC3[104]. In order to determine how truly selective the NKY80 molecule is, the inhibition capability of AC5 was compared to AC6, the two most closely related AC isoforms, in an AC activity assay (Figure 11A). AC5 was marginally more potently




Figure 10: Predicted Binding Conformation of NKY80. (A) Chemical structure of AC inhibitor NKY80. (B) Predicted binding conformation of NKY80 (cyan carbons) in AC catalytic site by AutoDock 4.2. NKY80 conformation is an overlay with of 2',3'-dd-ATP conformation (grey carbons) as reference. C1 domain is yellow, C2 domain is silver, manganese metal ion is orange. (C) Predicted binding conformation of NKY80 (cyan carbons) with AC catalytic site residues within 3.5 angstroms displayed (grey carbons).

inhibited than AC6 at each concentration of NKY80 used. This is shown by observed IC_{50} of 7.1 μ M for AC5 compared to 17 μ M for AC6, an approximately 2.5 fold difference. This potency shift was generally not significant at equivalent concentrations of NKY80, and it can be concluded that AC5 and AC6 are similarly inhibited by NKY80.

NKY80 Inhibition Curves for AC 1-9

With NKY80 shown to not have perfect AC5 isoform specificity, all 9 AC isoforms were tested in AC activity assays with NKY80 to determine how truly selective the small molecule inhibitor was (Figure 11B). AC1-7 were expressed in Sf9 membranes; as AC8 and AC9 do not express well in Sf9 membranes, expression in HEK membranes was instead used for these two isoforms. Results show that NKY80 inhibition of AC5 and AC6 is much more potent than inhibition of all other isoforms. There appears to be an intermediate potency group of AC1, AC3, and AC4, as well as a low potency group including AC2, AC7, AC8, and AC9. Unlike the more strongly inhibited AC5 and AC6 isoform group, these two other groupings do not follow the typically categorized AC isoform families with evolutionary similarity and higher overlap in regulators. Observed IC_{50} for AC2, AC3, and AC5 agree with previously published results[104], and interestingly the docking score for NKY80 to the 1CJT AC derived structure predicted affinity of NKY80 for AC was very close to the inhibition potency of NKY80 for AC5 (Table 2).

Summary

The small molecule AC inhibitor NKY80 was docked to AC structure with AutoDock 4.2, and its concentration-dependent ability to inhibit all 9 AC isoforms was characterized experimentally. Despite being advertised as an AC5 selective inhibitor, NKY80 also strongly inhibits the closely related isoform AC6. When compared to nonselective P-site inhibitors, the ring structure of NKY80 moves towards a predicted hydrogen bond with AC residue Asn1025.




Figure 11: Full AC Isoform Selectivity Characterization of NKY80. (A) Concentration curves of AC5 and AC6 inhibition by NKY80 from a representative experiment. 15 μg of membranes of indicated AC isoform stimulated by 50 μM forskolin, incubated with indicated concentration of inhibitor. $p < 0.05$ for *. (B) Concentration curves of NKY80 inhibition of transmembrane AC isoforms. 15 μg of membranes of indicated AC isoform stimulated by 50 μM forskolin, incubated with indicated concentration of inhibitor. AC isoform family is indicated by color of the inhibition curve; Group I AC's are red (AC1 = red, AC3 = dark red, AC8 = light red), Group II AC's are green (AC2 = green, AC4 = dark green, AC7 = light green), Group III AC's are blue (AC5 = blue, AC6 = cyan), AC9 is grey.

Table 2: Predicted and Experimental IC₅₀ for NKY80 Inhibition of Adenylyl Cyclase	
<u>AC Isoform</u>	<u>IC50</u>
1CJT AC Structure	Predicted (K _i): 8.61μM
AC1	Experimental: 92μM
AC2	Previously Published[104]: 1.7mM
	Experimental: >1mM
AC3	Previously Published[104]: 132μM
	Experimental: 127μM
AC4	Experimental: 114μM
AC5	Previously Published[104]: 8.3μM
	Experimental: 7.1μM
AC6	Experimental: 17μM
AC7	Experimental: >1mM
AC8	Experimental: >1mM
AC9	Experimental: >1mM

Chapter 6

Discussion

AC Isoform Groups and NKY80 Selectivity

It was expected that NKY80 selectivity for inhibiting AC isoforms would follow classic AC groups that are phylogenetically related and have closer patterns of regulation. These are Group 1 (AC1, AC3, and AC8), Group 2 (AC2, AC4, and AC7), Group 3 (AC5 and AC6), and Group 4 (AC9)[6]. Consistent with this prediction, NKY80 inhibited AC5 and AC6 much better than the other isoforms. However, the other inhibition curves surprisingly did not show separation of Group 1 and Group 2 AC isoforms. AC1, AC3, and AC4 had NKY80 IC_{50} in the high micromolar range, consistent with the previously published AC3 IC_{50} of approximately 132 μ M. AC2, AC7, AC8, and AC9 had NKY80 IC_{50} somewhere beyond the 1mM concentration tested. The IC_{50} of AC2 has previously been published to be about 1.2 mM; we assume that AC7, AC8, and AC9 remain on a similar inhibition curve beyond 1mM as AC2. These groupings also do not follow known similarities in AC isoform regulation. Lack of known isoform similarity for these groupings combined with the observed 10-fold differences in NKY80 inhibitory potential between AC isoforms being possible from minor changes in AC spatial conformation, the prospect of explaining the catalytic structure differences between the AC1/3/4 and AC2/7/8/9 groups seems unlikely. Determining why NKY80 inhibits AC5 and AC6 better than the remainder of AC isoforms is more probable, considering the greater similarity of these two AC isoforms.

Although NKY80 is described as an AC5 selective inhibitor, it strongly inhibits both AC5 and AC6. Supposed AC5 selectivity issues are not just restricted to AC inhibitors. The AC catalytic site is pseudosymmetrical, and the binding pocket for the AC activator forskolin is found opposite to the ATP binding site. Novel AC selective small molecule activators derived from forskolin have been developed that show selectivity for cardiac AC5 over AC2 and AC3,

but were not tested against the closely related AC6[106]. One of the activators developed is clinically approved for acute heart failure, colforsin daropate[71]. Considering the beneficial effects from AC6 activation for chronic heart failure, it seems reasonable to consider if colforsin daropate stimulates AC6 as well as AC5.

AC Catalytic Site Residues and Inhibitor Selectivity

Asn1025 is a residue in the catalytic site of AC that virtual docking of NKY80 suggests is involved in the ability of NKY80 to bind at the AC catalytic pocket. Asn1025 is conserved in all 9 isoforms, so why it would confer isoform selectivity to NKY80 is not immediately clear by a difference in isoform sequence. Thus, it is unclear if the cause for this residue's interaction with NKY80 is directly due to the residue or residue type, or if the interaction is induced by an isoform specific allosteric effect. However, it is clear that Asn1025 location or placement is important for NKY80 binding.


It is known that NKY80 is somewhat isoform selective, with a preference for inhibition of AC5[104] and, apparently, AC6. It is noteworthy that P-site inhibitors are one of two larger families of classic AC small molecule inhibitors. The other is MANT-nucleotide analogs of ATP. MANT-GTP and similar inhibitors share an increased inhibitory potency for AC5 and AC6, although with a less profound difference between these isoforms and others. The MANT group on these molecules, for example with MANT-GTP, binds to AC based on a crystal structure where there is structural helix movement to allow a new pocket that we shall call a "C" pocket in addition to the "A" and "B" inhibitor binding pockets used by P-site inhibitors[84]. The beginning of the opening to this extra "C" pocket, consisting of the $\alpha 1$ helix of the C1 domain and the $\alpha 4'$ helix of the C2 domain, lies just beyond Asn1025. The large

movement of these two helices accommodates the hydrophobic region which interacts with the MANT group, as seen when comparing the 1CJT and 1TL7 AC structures (Figure 12A). Hydrophobic region opening also includes significant movement of the sidechains for Thr401 and Asn1025, the residues noticed as possible causes for the selectivity of the novel AC1 inhibitors and NKY80 respectively. This is also supported by the $\alpha 1$ helix having isoform specific residue variability that is rare to find in the AC catalytic site (Figure 12B). More flexibility for AC5 and AC6 in this subregion would increase entropy, and thus make interaction of the subregion residues with inhibitors more energetically favorable. Thus, NKY80 and MANT-attached nucleotides may similarly interact with AC in this mobile subregion of the catalytic site conferring similar AC5 and AC6 selectivity.

Sites unique to the C1/C2 domains of AC5 and AC6 are not without precedence. The AC5/6 C1 domains both have a binding site for $G_i\alpha$, for example[107]. However, such regulatory sites can usually be identified in the AC primary sequence. Instead, in the case of NKY80 and MANT-GTP, it is possible that the AC5/6 isoform family is more flexible in this catalytic subregion bracketed by the $\alpha 1$ and $\alpha 4'$ helices, and thus more accommodating to stable conformations with interactions by these small molecule inhibitors.

NKY80 is similar in selectivity to the competitive inhibitor MANT-GTP, but is derived from uncompetitive P-site inhibitors. As NKY80 is also not a competitive inhibitor, this supports the development of novel isoform selective inhibitors that also do not have a competitive mechanism. As previously mentioned, one of the justifications for using P-site inhibitors as a template for a desired AC isoform selective therapeutic as opposed to MANT-nucleotides is the desire for an uncompetitive inhibitory mechanism. Uncompetitive inhibition causing decreased maximal cAMP concentrations capable by cardiac AC5 as a chronic heart

A



B

AC C1 $\alpha 1$ Sequence		AC C2 $\alpha 4'$ Sequence	
1CJT AC	399 GFTSLASQC 407	1CJT AC	1023 TVN ^B VASRMDSTG 1034
hAC1	311 GFTGLASQC 319	hAC1	1002 TVN ^B VASRMDSTG 1013
hAC2	298 GFTRLASDC 306	hAC2	1024 TVN ^B VASRMDSTG 1035
hAC3	327 GFTQLSSAC 335	hAC3	1067 TVN ^B VASRME ^R STG 1078
hAC4	281 GFTRLASEC 289	hAC4	1010 TVN ^B VASRME ^R STG 1021
hAC5	477 GFTSLASQC 485	hAC5	1202 TVN ^B VASRMDSTG 1213
hAC6	387 GFTSLASQC 395	hAC6	1110 TVN ^B VSSRMDSTG 1121
hAC7	287 GFTQLASDC 295	hAC7	1015 TVN ^B VASRME ^R STG 1026
hAC8	422 GFTNLST ^R TL 430	hAC8	1114 TVN ^L LASRMDSTG 1125
hAC9	402 GFTKMSANK 410	hAC9	1190 TVN ^I ASRMD ^T TG 1201

Figure 12: Structural Flexibility in the AC Catalytic Site. (A) Overlay of crystal structures of AC catalytic site from 2',3'-dd-ATP (PDB ID 1CJT; C1 = yellow, C2 = silver) and MANT-GTP (PDB ID 1TL7; C1 = tan, C2 = black). Manganese metal ion is orange and labeled. Positions of Thr401 and Asn1025 indicated for 1CJT with cyan carbons, for 1TL7 with grey carbons. The $\alpha 1$ and $\alpha 4'$ helices of AC are also labeled. (B) Primary sequence alignments for $\alpha 1$ and $\alpha 4'$ helix domains of crystal AC structure, human AC's 1-9. Residues that differ from the primary sequence of the 1CJT crystal structure C1/C2 domains are red. Residue Thr401 in the AC C1 sequence alignment is blue. Residue Asn1025 in the AC C2 sequence alignment is green.

failure treatment, for example, would still allow lower levels of cAMP activity. Thus, such a mechanism would likely make long term treatment easier by not shutting down AC5/cAMP

pathways completely. By contrast, a competitive inhibitor's safe dosage could be more sensitive to local concentrations of ATP. It will be of great interest to determine what mechanism is used by selective AC inhibitors produced by optimization of the novel ChemBridge inhibitors that have been identified.

Chemical Groups Important for NKY80 Inhibition of AC

There are two main differences between NKY80 and classic P-site inhibitors in chemical structure that are apparent when comparing their binding conformations. One, as previously mentioned, is hydrogen bonding of the NKY80 furan ring with Asn1025, which involves a movement of that ring away from where a P-site inhibitor's ribose ring is oriented. This could explain both a phosphate-less nanomolar potency for NKY80 and/or the inhibitor's selectivity, as it is the beginning of a catalytic site subregion with flexibility that may accommodate isoform specific interactions. Crystal structures of AC with bound MANT-nucleotide inhibitors where the MANT group interacts in this subregion support such a claim[84]. Additionally, the slight selectivity in P-site inhibitor derived compounds for AC5 was first noticed when the ribose ring of classic P-site inhibitors was modified to a furan ring to create the small molecule inhibitor SQ22536[104]. This suggests further that interaction of a furan ring with the catalytic residue Asn1025 is a significant part of the explanation for the observed AC5/AC6 inhibitor selectivity for NKY80 and structurally related selective compounds. Modifications to the furan ring of NKY80 resulting in a decrease in NKY80 potency also support this chemical group's importance for inhibitor potency in the absence of phosphates, research that was notably done with an aim of targeting cardiac AC5[105].

Regrettably, many small molecule AC inhibitors have not been characterized for inhibition potency of both AC5 and AC6.

The other noteworthy difference between NKY80 and classic P-site inhibitors is the carbonyl group of NKY80. This chemical property of NKY80 is more closely related to the structure of guanine or inosine based inhibitors such as MANT-GTP and MANT-ITP, as opposed to adenine based inhibitors such as MANT-ATP or the classic P-site inhibitors. Based on its predicted binding position, the carbonyl oxygen points out into what is essentially open space; there is no clearly interacting AC residue within 3.5 Å. By comparison, MANT-GTP has a hydrogen bond between its carbonyl and AC residue Lys938 in the “A” pocket[84]. Additionally, no residues appear to be significantly closer to this group than they would be to a similar oxygen-containing group in the P-site inhibitor structure. It is possible that other effects, such as solvation with water molecules, could allow this carbonyl to interact with residues further away in the AC catalytic site, conferring inhibitor potency and/or AC isoform selectivity. As these docking experiments were done in the absence of water, it cannot be currently determined if there is such a solvation effect.

Comparison of NKY80 to Other AC Inhibitors

HTS09836, as previously mentioned, is a patented AC1 selective inhibitor[103, 108]. In Asia it is an orally available analgesic treatment. It is capable of crossing cell membranes, a significant obstacle in the development of classic P-site inhibitors and MANT-nucleotides as therapeutics. NKY80 is reported not to work in cell-based assays. This is surprising as the extremely similar inhibitor it is derived from, SQ22536, is slightly less selective but despite an intact adenine ring can inhibit AC activity in cells[105]. However, this maintained adenine ring

eliminates SQ22536 from further therapeutic development, as the off-target effects on DNA synthesis that are possible are greatly undesired for a specific drug.

Small molecule inhibitors of AC such as tryphostins and catechol oestrogens offer an alternative to the more well characterized P-site inhibitors and MANT-nucleotide inhibitors as drug development templates, and these molecules appear to have some isoform specificity[102]. However, their binding site is distinct from the ATP binding position used by P-site inhibitors and MANT-nucleotides, and they require direct interaction with metal ions. To date, published inhibitors using this pocket have only targeted sAC and can differentiate between the 9 membrane-bound isoforms of AC and sAC[109]. Nonetheless, some small molecules derived from P-site inhibitors show promise with integrating these metal chelating properties and isoform selectivity, such as PMC-6[100]. Combining the best inhibitor characteristics of PMC-6 and NKY80 may be the path ahead for making therapeutic inhibitors that preferentially target AC5 and/or AC6.

Although it turns out that NKY80 strongly inhibits both AC5 and AC6, other inhibitors at the catalytic site are capable of inhibiting one of these closely related isoforms better than the other. The small molecule inhibitor 2'-d-3'-MANT-GDP has a K_i for AC1 at 1.7 nM and AC6 at 3.1 nM, while AC2 and AC5 K_i were determined to be 21 and 25 nM respectively[83]. Reported AC5 inhibitors that do not inhibit AC6 include the antiviral drug Ara-A (also known as vidarabine). Although used originally as an FDA-approved antiviral, Ara-A has recently become of interest in cases of chronic heart failure. Ara-A shows some selectivity for inhibiting AC5 but not AC6 at a concentration of 10 μ M in cardiomyocyte membranes and intact cells[110, 111]. Its mechanism and inhibitory profile in comparison to NKY80 is of great interest, as the two are structurally similar.

Cardiac Complexes of AC5/AC6 and Inhibitor Selectivity

Preliminary results indicate that it cannot be ruled out that Ara-A's effects are specific to the cardiac cell type. Although not completely surprising considering its great similarity to adenosine and already characterized effect as an antiviral drug, off-target effects are not the only possible explanation for cell-specific Ara-A effects. It may also be that AC5 and AC6 cardiac complexes in a chronic heart failure setting have cell and isoform specific regulation that affect baseline isoform activity, showing greater % inhibition for AC5 from Ara-A and similar compounds.

If cardiac specific AC complexes are influencing AC5/AC6 inhibitor sensitivity, the specificity of signaling complexes including AC are further supported as being important for regulation of AC and the resulting local pools of cAMP. One example is those complexes formed by A-kinase anchoring proteins (AKAPs). AKAPs all anchor protein kinase A (PKA) as well as a more AKAP-specific complement of other kinases and phosphatases. AKAP complex-dependent kinase activity has been shown previously[112]. In addition, AKAP complexes with specific AC isoforms have been shown in cardiac cell types[45, 113-116]. The ability of EGF to increase cAMP accumulation in cardiomyocytes but not non-cardiac cells expressing a similar complement of AC isoforms further supports differences in cell specific AC isoform complexing[117]. Compartmentalized cAMP production in cardiac cells as would be expected has been previously shown[118], along with dynamic changes in the cAMP pool due to upstream adrenergic receptor specific signaling[119]. Effects of cell and isoform specific regulatory signaling complexes could explain the differences in selectivity seen for allegedly

AC5 selective inhibitors related to NKY80 in different assays, such as PMC-6[105] and Ara-A[110, 111].

It is also possible that heterodimerization of AC isoforms may be an influence on perceived isoform selective inhibition. It has been suggested for some time that dimerized AC exists, both through biochemical[120] and FRET-based[121] methods. AC associates in dimeric complexes through their transmembrane domains, as has been shown for AC6[122]. AC5 cooperativity in G α stimulation differs from Michaelis-Menten kinetics for stimulation of AC6[24]; it has been suggested that this can be explained by AC5 dimerization both in that work and elsewhere[123]. In cardiac complexes, one possible explanation could be that AC5 expression models involve homodimers, whereas AC6 expression in the same cardiac cells results in heterodimerization with an AC isoform less sensitive to inhibitors such as NKY80 or Ara-A. Thus, cardiac models produced by AC5 overexpression would be much more sensitive to these compounds than those produced by AC6 overexpression.

There is physiological precedence for differences between AC5 and AC6 regulation that are tissue dependent. Nitric oxide indirectly inhibits both AC5 and AC6 in N18TG2 cell membranes[124], but only inhibits AC6 in COS-7 cells[125]. Supporting that such regulation differs due to tissue-dependent AC5 and AC6 specific signaling complexes, it has also been shown that localization to caveolae is required for nitric oxide mediated inhibition of AC6 in cardiomyocytes[126]. Cardiac caveolae-based complexes are also required for the organization of different forms of AC5 regulation, including calcium inhibition by capacitative Ca²⁺ entry[127] and stimulation by upstream GPCRs[128].

The main implications tissue-dependent AC complexes would have for development of a small molecule inhibitor with therapeutic potential are twofold. First, tissue selectivity could

be derived for an AC inhibitor by targeting tissue specific complexes. Second, separating AC5 and AC6 selectivity in a small molecule inhibitor would not be necessary as long as the differences in AC5 and AC6 cardiac complexes influencing their inhibition sensitivity were known.

Future Directions

With the possible furan and carbonyl moiety trends for AC5 selectivity in NKY80, Ara-A, and similar discovered novel AC inhibitors, drug optimization using these chemical groups can be used to determine their necessity for potent inhibition of AC and/or isoform selectivity. Additionally, using the crystal structure of MANT-GTP bound to AC, the screen for novel AC inhibitors can be repeated to see what small molecules overlap and bind tightly in both structures, as well as which novel inhibitors are predicted to interact in the novel “C” pocket where MANT binds. This will be particularly critical for determining isoform selectivity characteristics of the novel ChemBridge inhibitors. Their predicted binding positions showed no clear reasons for selectivity, but a second AC conformation may provide a better fit for the predicted binding position of these compounds and better explain their observed isoform selectivity.

Such inhibitors can be further optimized by searching the ChemBridge virtual screening results for structurally similar ligands that can also be tested for AC inhibition. Additionally, other drug-like small molecule libraries can be tested with a more focused effort on identifying AC inhibitors with chemical groups that give isoform selectivity, such the furan ring that is part of NKY80. In order to better explore the capability of inhibitors to pass the cell membrane and

work in human cells to inhibit cAMP production, the novel inhibitors already identified and any more found from optimized screens should also be tested in cell-based assays.

Lastly, it is worth noting that the crystal structures being used, although equivalent to human AC5 at the catalytic site, are not the same throughout their amino acid sequence. Should a structural model be crystallized with human C1/C2 domains, dynamic docking of inhibitors with known or produced isoform selectivity profiles can be performed to better observe flexible changes in AC structure that may confer isoform selective characteristics.

Summary

Although conserved across all AC isoforms, structural flexibility may allow AC residue Asn1025 to confer AC5/6 selectivity to the small molecule inhibitor NKY80. Targeting of Asn1025 and the large hydrophobic patch behind it between the $\alpha 1$ and $\alpha 4'$ helices may be useful for producing isoform selective AC inhibitors, and to understand subtle differences between the AC isoforms in the well conserved catalytic area.

Bibliography

1. E.W. Sutherland and T.W. Rall, *Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles*. J Biol Chem, 1958. 232(2): p. 1077-91.
2. M. Kamenetsky, S. Middelhaufe, E.M. Bank, L.R. Levin, J. Buck, and C. Steegborn, *Molecular details of cAMP generation in mammalian cells: a tale of two systems*. J Mol Biol, 2006. 362(4): p. 623-39.
3. J. Krupinski, F. Coussen, H.A. Bakalyar, W.J. Tang, P.G. Feinstein, K. Orth, C. Slaughter, R.R. Reed, and A.G. Gilman, *Adenylyl cyclase amino acid sequence: possible channel- or transporter-like structure*. Science, 1989. 244: p. 1558.
4. R. Sadana, N. Dascal, and C.W. Dessauer, *N terminus of type 5 adenylyl cyclase scaffolds Gs heterotrimer*. Mol Pharmacol, 2009. 76(6): p. 1256-64.
5. J.J.G. Tesmer, R.K. Sunahara, A.G. Gilman, and S.R. Sprang, *Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gs α .GTP γ S*. Science, 1997. 278: p. 1907.
6. R. Sadana and C.W. Dessauer, *Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies*. Neurosignals, 2009. 17(1): p. 5-22.
7. C. Pinto, M. Hubner, A. Gille, M. Richter, T.C. Mou, S.R. Sprang, and R. Seifert, *Differential interactions of the catalytic subunits of adenylyl cyclase with forskolin analogs*. Biochem Pharmacol, 2009. 78(1): p. 62-9.
8. E.M. Ross and A.G. Gilman, *Resolution of some components of adenylate cyclase necessary for catalytic activity*. J Biol Chem, 1977. 252(20): p. 6966-9.

9. E.M. Ross and A.G. Gilman, *Reconstitution of catecholamine-sensitive adenylate cyclase activity: interactions of solubilized components with receptor-replete membranes*. Proc Natl Acad Sci U S A, 1977. 74(9): p. 3715-9.
10. E.M. Ross, M.E. Maguire, T.W. Sturgill, R.L. Biltonen, and A.G. Gilman, *Relationship between the beta-adrenergic receptor and adenylate cyclase*. J Biol Chem, 1977. 252(16): p. 5761-75.
11. B.M. Hacker, J.E. Tomlinson, G.A. Wayman, R. Sultana, G. Chan, E. Villacres, C. Disteché, and D.R. Storm, *Cloning, chromosomal mapping, and regulatory properties of the human type 9 adenylyl cyclase (ADCY9)*. Genomics, 1998. 50(1): p. 97-104.
12. X. Gao, R. Sadana, C.W. Dessauer, and T.B. Patel, *Conditional stimulation of type V and VI adenylyl cyclases by G protein betagamma subunits*. J Biol Chem, 2007. 282(1): p. 294-302.
13. W.J. Tang and A.G. Gilman, *Type-specific regulation of adenylyl cyclase by G protein beta gamma subunits*. Science, 1991. 254(5037): p. 1500-3.
14. B. Hu, H. Nakata, C. Gu, T. De Beer, and D.M. Cooper, *A critical interplay between Ca²⁺ inhibition and activation by Mg²⁺ of AC5 revealed by mutants and chimeric constructs*. J Biol Chem, 2002. 277(36): p. 33139-47.
15. T. Mitterauer, M. Hohenegger, W.J. Tang, C. Nanoff, and M. Freissmuth, *The C2 catalytic domain of adenylyl cyclase contains the second metal ion (Mn²⁺) binding site*. Biochemistry, 1998. 37(46): p. 16183.

16. J.J. Tesmer, R.K. Sunahara, R.A. Johnson, G. Gosselin, A.G. Gilman, and S.R. Sprang, *Two-metal-Ion catalysis in adenylyl cyclase*. *Science*, 1999. 285(5428): p. 756.
17. K.B. Seamon and J.W. Daly, *Forskolin: its biological and chemical properties*. *Adv Cyclic Nucleotide Protein Phosphorylation Res*, 1986. 20: p. 1.
18. E.M. Sutkowski, W.J. Tang, C.W. Broome, J.D. Robbins, and K.B. Seamon, *Regulation of forskolin interaction with type I, II, V, and VI adenylyl cyclases by G s* à *Biochemistry*, 1994. 33: p. 12852.
19. C.W. Dessauer, T.T. Scully, and A.G. Gilman, *Interactions of forskolin and ATP with the cytosolic domains of mammalian adenylyl cyclase*. *J Biol Chem*, 1997. 272: p. 22272.
20. S.Z. Yan, Z.H. Huang, R.K. Andrews, and W.J. Tang, *Conversion of forskolin-insensitive to forskolin-sensitive (mouse-type IX) adenylyl cyclase*. *Mol Pharmacol*, 1998. 53(2): p. 182.
21. J.L. Guillou, H. Nakata, and D.M. Cooper, *Inhibition by calcium of mammalian adenylyl cyclases*. *J Biol Chem*, 1999. 274(50): p. 35539-45.
22. G. Iwami, J. Kawabe, T. Ebina, P.J. Cannon, C.J. Homcy, and Y. Ishikawa, *Regulation of adenylyl cyclase by protein kinase A*. *J Biol Chem*, 1995. 270(21): p. 12481-4.
23. B.D. Carter and F. Medzihradsky, *Go mediates the coupling of the mu opioid receptor to adenylyl cyclase in cloned neural cells and brain*. *Proc Natl Acad Sci U S A*, 1993. 90(9): p. 4062-6.

24. M. Chen-Goodspeed and C.W. Dessauer, *Differential Regulation of Human type V and VI Adenylyl Cyclase by Gi and Gs alpha*. J Biol Chem, 2004. in press.
25. J. Kawabe, G. Iwami, T. Ebina, S. Ohno, T. Katada, Y. Ueda, C.J. Homcy, and Y. Ishikawa, *Differential activation of adenylyl cyclase by protein kinase C isoenzymes*. J Biol Chem, 1994. 269: p. 16554.
26. H.L. Lai, T.H. Yang, R.O. Messing, Y.H. Ching, S.C. Lin, and Y. Chern, *Protein kinase C inhibits adenylyl cyclase type VI activity during desensitization of the A2a-adenosine receptor-mediated cAMP response*. J Biol Chem, 1997. 272(8): p. 4970.
27. G. Zimmermann and R. Taussig, *Protein kinase C alters the responsiveness of adenylyl cyclases to G protein alpha and betagamma subunits*. J Biol Chem, 1996. 271(43): p. 27161.
28. M.A. Beazely and V.J. Watts, *Galphaq-coupled receptor signaling enhances adenylyl cyclase type 6 activation*. Biochem Pharmacol, 2005. 70(1): p. 113-20.
29. F.A. Antoni, U.K. Wiegand, J. Black, and J. Simpson, *Cellular localisation of adenylyl cyclase: a post-genome perspective*. Neurochem Res, 2006. 31(2): p. 287-95.
30. J.D. Corbin, T.R. Soderling, and C.R. Park, *Regulation of adenosine 3',5'-monophosphate-dependent protein kinase. I. Preliminary characterization of the adipose tissue enzyme in crude extracts*. J Biol Chem, 1973. 248(5): p. 1813-21.
31. Z.L. Wu, S.A. Thomas, E.C. Villacres, Z.G. Xia, M.L. Simmons, C. Chavkin, R.D. Palmiter, and D.R. Storm, *Altered behavior and long-term potentiation in type I adenylyl cyclase mutant mice*. Proc Natl Acad Sci U S A, 1995. 92: p. 220.

32. D.R. Storm, C. Hansel, B. Hacker, A. Parent, and D.J. Linden, *Impaired cerebellar long-term potentiation in type I adenylyl cyclase mutant mice*. *Neuron*, 1998. 20(6): p. 1199-210.
33. J. Liauw, L.J. Wu, and M. Zhuo, *Calcium-stimulated adenylyl cyclases required for long-term potentiation in the anterior cingulate cortex*. *J Neurophysiol*, 2005. 94(1): p. 878-82.
34. H. Wang, V.V. Pineda, G.C. Chan, S.T. Wong, L.J. Muglia, and D.R. Storm, *Type 8 adenylyl cyclase is targeted to excitatory synapses and required for mossy fiber long-term potentiation*. *J Neurosci*, 2003. 23(30): p. 9710-8.
35. H. Wang, G.D. Ferguson, V.V. Pineda, P.E. Cundiff, and D.R. Storm, *Overexpression of type-I adenylyl cyclase in mouse forebrain enhances recognition memory and LTP*. *Nat Neurosci*, 2004. 7(6): p. 635-42.
36. S.T. Wong, J. Athos, X.A. Figueroa, V.V. Pineda, M.L. Schaefer, C.C. Chavkin, L.J. Muglia, and D.R. Storm, *Calcium-stimulated adenylyl cyclase activity is critical for hippocampus-dependent long-term memory and late phase LTP*. *Neuron*, 1999. 23(4): p. 787-98.
37. T. Donohue, P.L. Hoffman, and B. Tabakoff, *Effect of ethanol on DARPP-32 phosphorylation in transgenic mice that express human type VII adenylyl cyclase in brain*. *Alcohol Clin Exp Res*, 2005. 29(3): p. 310-6.
38. B. Duan, R. Davis, E.L. Sadat, J. Collins, P.C. Sternweis, D. Yuan, and L.I. Jiang, *Distinct roles of adenylyl cyclase VII in regulating the immune responses in mice*. *J Immunol*, 2010. 185(1): p. 335-44.

39. S.T. Wong, K. Trinh, B. Hacker, G.C. Chan, G. Lowe, A. Gaggar, Z. Xia, G.H. Gold, and D.R. Storm, *Disruption of the type III adenylyl cyclase gene leads to peripheral and behavioral anosmia in transgenic mice*. *Neuron*, 2000. 27(3): p. 487-97.
40. Z. Wang, C. Balet Sindreu, V. Li, A. Nudelman, G.C. Chan, and D.R. Storm, *Pheromone detection in male mice depends on signaling through the type 3 adenylyl cyclase in the main olfactory epithelium*. *J Neurosci*, 2006. 26(28): p. 7375-9.
41. J.L. Pluznick, D.J. Zou, X. Zhang, Q. Yan, D.J. Rodriguez-Gil, C. Eisner, E. Wells, C.A. Greer, T. Wang, S. Firestein, J. Schnermann, and M.J. Caplan, *Functional expression of the olfactory signaling system in the kidney*. *Proc Natl Acad Sci U S A*, 2009. 106(6): p. 2059-64.
42. G. Livera, F. Xie, M.A. Garcia, B. Jaiswal, J. Chen, E. Law, D.R. Storm, and M. Conti, *Inactivation of the mouse adenylyl cyclase 3 gene disrupts male fertility and spermatozoon function*. *Mol Endocrinol*, 2005. 19(5): p. 1277-90.
43. G. Esposito, B.S. Jaiswal, F. Xie, M.A. Krajnc-Franken, T.J. Robben, A.M. Strik, C. Kuil, R.L. Philipsen, M. van Duin, M. Conti, and J.A. Gossen, *Mice deficient for soluble adenylyl cyclase are infertile because of a severe sperm-motility defect*. *Proc Natl Acad Sci U S A*, 2004. 101(9): p. 2993-8.
44. L.R. Fraser, S. Adeoya-Osiguwa, R.W. Baxendale, S. Mededovic, and O.O. Osiguwa, *First messenger regulation of mammalian sperm function via adenylyl cyclase/cAMP*. *J Reprod Dev*, 2005. 51(1): p. 37-46.

45. Y. Li, L. Chen, R.S. Kass, and C.W. Dessauer, *The A-kinase anchoring protein Yotiao facilitates complex formation between adenylyl cyclase type 9 and the IKs potassium channel in heart*. *J Biol Chem*, 2012. 287(35): p. 29815-24.
46. L. Liu, S. Das, W. Losert, and C.A. Parent, *mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion*. *Dev Cell*, 2010. 19(6): p. 845-57.
47. K.S. Kim, J. Kim, S.K. Back, J.Y. Im, H.S. Na, and P.L. Han, *Markedly attenuated acute and chronic pain responses in mice lacking adenylyl cyclase-5*. *Genes Brain Behav*, 2007. 6(2): p. 120-7.
48. F.Q. Cunha, M.M. Teixeira, and S.H. Ferreira, *Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia*. *Br J Pharmacol*, 1999. 127(3): p. 671-8.
49. T. Avidor-Reiss, I. Nevo, D. Saya, M. Bayewitch, and Z. Vogel, *Opiate-induced adenylyl cyclase superactivation is isozyme-specific*. *J Biol Chem*, 1997. 272(8): p. 5040-7.
50. M.G. Cumbay and V.J. Watts, *Heterologous sensitization of recombinant adenylate cyclases by activation of D(2) dopamine receptors*. *J Pharmacol Exp Ther*, 2001. 297(3): p. 1201-9.
51. I. Nevo, T. Avidor-Reiss, R. Levy, M. Bayewitch, E. Heldman, and Z. Vogel, *Regulation of adenylyl cyclase isozymes on acute and chronic activation of inhibitory receptors*. *Mol Pharmacol*, 1998. 54(2): p. 419-26.
52. V.J. Watts, R. Taussig, R.L. Neve, and K.A. Neve, *Dopamine D2 receptor-induced heterologous sensitization of adenylyl cyclase requires Galphas: characterization of*

- Galphas-insensitive mutants of adenylyl cyclase V. Mol Pharmacol, 2001. 60(6): p. 1168-72.*
53. K.S. Kim, K.W. Lee, J.Y. Im, J.Y. Yoo, S.W. Kim, J.K. Lee, E.J. Nestler, and P.L. Han, *Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action. Proc Natl Acad Sci U S A, 2006. 103(10): p. 3908-13.*
54. T. Iwamoto, S. Okumura, K. Iwatsubo, J. Kawabe, K. Ohtsu, I. Sakai, Y. Hashimoto, A. Izumitani, K. Sango, K. Ajiki, Y. Toya, S. Umemura, Y. Goshima, N. Arai, S.F. Vatner, and Y. Ishikawa, *Motor dysfunction in type 5 adenylyl cyclase-null mice. J Biol Chem, 2003. 278(19): p. 16936.*
55. K.W. Lee, J.H. Hong, I.Y. Choi, Y. Che, J.K. Lee, S.D. Yang, C.W. Song, H.S. Kang, J.H. Lee, J.S. Noh, H.S. Shin, and P.L. Han, *Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase. J Neurosci, 2002. 22(18): p. 7931.*
56. N. Defer, M. Best-Belpomme, and J. Hanoune, *Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Renal Physiol, 2000. 279(3): p. F400-16.*
57. M. Iwase, M. Uechi, D.E. Vatner, K. Asai, R.P. Shannon, R.K. Kudej, T.E. Wagner, D.C. Wight, T.A. Patrick, Y. Ishikawa, C.J. Homcy, and S.F. Vatner, *Cardiomyopathy induced by cardiac Gs alpha overexpression. Am J Physiol, 1997. 272(1 Pt 2): p. H585-9.*
58. S. Engelhardt, L. Hein, F. Wiesmann, and M.J. Lohse, *Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A, 1999. 96(12): p. 7059-64.*

59. C.L. Antos, N. Frey, S.O. Marx, S. Reiken, M. Gaburjakova, J.A. Richardson, A.R. Marks, and E.N. Olson, *Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a*. *Circ Res*, 2001. 89(11): p. 997-1004.
60. A.T. Yan, R.T. Yan, and P.P. Liu, *Narrative review: pharmacotherapy for chronic heart failure: evidence from recent clinical trials*. *Ann Intern Med*, 2005. 142(2): p. 132-45.
61. I. Espinasse, V. Iourgenko, N. Defer, F. Samson, J. Hanoune, and J.J. Mercadier, *Type V, but not type VI, adenylyl cyclase mRNA accumulates in the rat heart during ontogenic development. Correlation with increased global adenylyl cyclase activity*. *J Mol Cell Cardiol*, 1995. 27(9): p. 1789.
62. T. Wang and M.J. Brown, *Differential expression of adenylyl cyclase subtypes in human cardiovascular system*. *Mol Cell Endocrinol*, 2004. 223(1-2): p. 55-62.
63. S. Okumura, G. Takagi, J. Kawabe, G. Yang, M.C. Lee, C. Hong, J. Liu, D.E. Vatner, J. Sadoshima, S.F. Vatner, and Y. Ishikawa, *Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload*. *Proc Natl Acad Sci U S A*, 2003. 100(17): p. 9986.
64. S. Okumura, J. Kawabe, A. Yatani, G. Takagi, M.C. Lee, C. Hong, J. Liu, I. Takagi, J. Sadoshima, D.E. Vatner, S.F. Vatner, and Y. Ishikawa, *Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation*. *Circ Res*, 2003. 93(4): p. 364.
65. S. Okumura, D.E. Vatner, R. Kurotani, Y. Bai, S. Gao, Z. Yuan, K. Iwatsubo, C. Ulucan, J. Kawabe, K. Ghosh, S.F. Vatner, and Y. Ishikawa, *Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal*

- and increases Akt signal with chronic catecholamine stress. Circulation, 2007. 116(16): p. 1776-83.*
66. L. Yan, D.E. Vatner, J.P. O'Connor, A. Ivessa, H. Ge, W. Chen, S. Hirotsu, Y. Ishikawa, J. Sadoshima, and S.F. Vatner, *Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell, 2007. 130(2): p. 247-58.*
67. T. Tang, N.C. Lai, D.M. Roth, J. Drumm, T. Guo, K.W. Lee, P.L. Han, N. Dalton, and M.H. Gao, *Adenylyl cyclase type V deletion increases basal left ventricular function and reduces left ventricular contractile responsiveness to beta-adrenergic stimulation. Basic Res Cardiol, 2006. 101(2): p. 117-26.*
68. S. Pierre, T. Eschenhagen, G. Geisslinger, and K. Scholich, *Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov, 2009. 8(4): p. 321-35.*
69. T.M. Griffith, A.T. Chaytor, D.H. Edwards, F. Daverio, and C. McGuigan, *Enhanced inhibition of the EDHF phenomenon by a phenyl methoxyalaninyl phosphoramidate derivative of dideoxyadenosine. Br J Pharmacol, 2004. 142(1): p. 27-30.*
70. W.H. Laux, P. Pande, I. Shoshani, J. Gao, V. Boudou-Vivet, G. Gosselin, and R.A. Johnson, *Pro-nucleotide inhibitors of adenylyl cyclases in intact cells. J Biol Chem, 2004. 279(14): p. 13317-32.*
71. M. Kikura, K. Morita, and S. Sato, *Pharmacokinetics and a simulation model of colforsin daropate, new forskolin derivative inotropic vasodilator, in patients undergoing coronary artery bypass grafting. Pharmacol Res, 2004. 49(3): p. 275-81.*
72. M. Yoneyama, A. Sugiyama, Y. Satoh, A. Takahara, Y. Nakamura, and K. Hashimoto, *Cardiovascular and adenylate cyclase stimulating effects of colforsin*

- daropate, a water-soluble forskolin derivative, compared with those of isoproterenol, dopamine and dobutamine. Circ J, 2002. 66(12): p. 1150-4.*
73. N.C. Lai, T. Tang, M.H. Gao, M. Saito, T. Takahashi, D.M. Roth, and H.K. Hammond, *Activation of cardiac adenylyl cyclase expression increases function of the failing ischemic heart in mice. J Am Coll Cardiol, 2008. 51(15): p. 1490-7.*
74. C.W. Dessauer and A.G. Gilman, *The catalytic mechanism of mammalian adenylyl cyclase: equilibrium binding and kinetic analysis of P-site inhibition. J Biol Chem, 1997. 272: p. 27787.*
75. C.W. Dessauer, J.J. Tesmer, S.R. Sprang, and A.G. Gilman, *The interactions of adenylate cyclases with P-site inhibitors. Trends in Pharmacological Sciences, 1999. 20(5): p. 205.*
76. J.J. Tesmer, C.W. Dessauer, R.K. Sunahara, L.D. Murray, R.A. Johnson, A.G. Gilman, and S.R. Sprang, *Molecular basis for P-site inhibition of adenylyl cyclase. Biochemistry, 2000. 39(47): p. 14464-71.*
77. L. Desaubry, I. Shoshani, and R.A. Johnson, *Inhibition of adenylyl cyclase by a family of newly synthesized adenine nucleoside 3'-polyphosphates. J Biol Chem, 1996. 271(24): p. 14028.*
78. L. Desaubry, I. Shoshani, and R.A. Johnson, *2',5'-Dideoxyadenosine 3'-polyphosphates are potent inhibitors of adenylyl cyclase. J Biol Chem, 1996. 271: p. 2380.*
79. L. Desaubry and R.A. Johnson, *Adenine nucleoside 3'-tetrphosphates are novel and potent inhibitors of adenylyl cyclases. J Biol Chem, 1998. 273(38): p. 24972.*

80. I. Shoshani, V. Boudou, C. Pierra, G. Gosselin, and R.A. Johnson, *Enzymatic synthesis of unlabeled and beta-(32)P-labeled beta-L-2', 3'-dideoxyadenosine-5'-triphosphate as a potent inhibitor of adenylyl cyclases and its use as reversible binding ligand*. *J Biol Chem*, 1999. 274(49): p. 34735-41.
81. R.A. Johnson, L. Desaubry, G. Bianchi, I. Shoshani, E. Lyons, Jr., R. Taussig, P.A. Watson, J.J. Cali, J. Krupinski, J.P. Pieroni, and R. Iyengar, *Isozyme-dependent sensitivity of adenylyl cyclases to P-site-mediated inhibition by adenine nucleosides and nucleoside 3'-polyphosphates*. *J Biol Chem*, 1997. 272(14): p. 8962-6.
82. A. Gille and R. Seifert, *2'(3')-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors*. *J Biol Chem*, 2003. 278(15): p. 12672-9.
83. A. Gille, G.H. Lushington, T.C. Mou, M.B. Doughty, R.A. Johnson, and R. Seifert, *Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides*. *J Biol Chem*, 2004. 279(19): p. 19955-69.
84. T.C. Mou, A. Gille, D.A. Fancy, R. Seifert, and S.R. Sprang, *Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2'(3')-O-(N-Methylanthraniloyl)-guanosine 5'-triphosphate*. *J Biol Chem*, 2005. 280(8): p. 7253-61.
85. T.C. Mou, A. Gille, S. Suryanarayana, M. Richter, R. Seifert, and S.R. Sprang, *Broad specificity of mammalian adenylyl cyclase for interaction with 2',3'-substituted purine- and pyrimidine nucleotide inhibitors*. *Mol Pharmacol*, 2006. 70(3): p. 878-86.
86. D. Rottlaender, J. Matthes, S.F. Vatner, R. Seifert, and S. Herzig, *Functional adenylyl cyclase inhibition in murine cardiomyocytes by 2'(3')-O-(N-*

- methylanthraniloyl)-guanosine 5'-[gamma-thio]triphosphate. J Pharmacol Exp Ther, 2007. 321(2): p. 608-15.*
87. B.J. Grant, S. Lukman, H.J. Hocker, J. Sayyah, J.H. Brown, J.A. McCammon, and A.A. Gorfe, *Novel allosteric sites on Ras for lead generation. PLoS One, 2011. 6(10): p. e25711.*
88. R. Huey, G.M. Morris, A.J. Olson, and D.S. Goodsell, *A semiempirical free energy force field with charge-based desolvation. J Comput Chem, 2007. 28(6): p. 1145-52.*
89. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson, *AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem, 2009. 30(16): p. 2785-91.*
90. Y. Salomon, C. Londos, and M. Rodbell, *A highly sensitive adenylate cyclase assay. Anal Biochem, 1974. 58: p. 541.*
91. R.E. Whisnant, A.G. Gilman, and C.W. Dessauer, *Interaction of the two cytosolic domains of mammalian adenylyl cyclase. Proc Natl Acad Sci U S A, 1996. 93: p. 6621.*
92. S.Z. Yan, D. Hahn, Z.H. Huang, and W.J. Tang, *Two cytoplasmic domains of mammalian adenylyl cyclase form a G_s α - and forskolin-activated enzyme in vitro. J Biol Chem, 1996. 271: p. 10941.*
93. R.K. Sunahara, C.W. Dessauer, R.E. Whisnant, C. Kleuss, and A.G. Gilman, *Interaction of G_s α with the cytosolic domains of mammalian adenylyl cyclase. J Biol Chem, 1997. 272: p. 22265.*
94. G. Zhang, Y. Liu, A.E. Ruoho, and J.H. Hurley, *Structure of the adenylyl cyclase catalytic core. Nature, 1997. 386: p. 247.*

95. T.C. Mou, N. Masada, D.M. Cooper, and S.R. Sprang, *Structural basis for inhibition of mammalian adenylyl cyclase by calcium*. *Biochemistry*, 2009. 48(15): p. 3387-97.
96. R.A. Johnson and I. Shoshani, *Kinetics of "P"-site-mediated inhibition of adenylyl cyclase and the requirements for substrate*. *J Biol Chem*, 1990. 265(20): p. 11595-600.
97. R.A. Johnson, S.M. Yeung, D. Stubner, M. Bushfield, and I. Shoshani, *Cation and structural requirements for P site-mediated inhibition of adenylate cyclase*. *Mol Pharmacol*, 1989. 35(5): p. 681-8.
98. D. Levy, C. Marlowe, K. Kane-Maguire, M. Bao, D. Cherbavaz, J. Tomlinson, D. Sedlock, and R. Scarborough, *Hydroxamate based inhibitors of adenylyl cyclase. Part 1: the effect of acyclic linkers on P-site binding*. *Bioorg Med Chem Lett*, 2002. 12(21): p. 3085-8.
99. D. Levy, M. Bao, J. Tomlinson, and R. Scarborough, *Hydroxamate based inhibitors of adenylyl cyclase. Part 2: the effect of cyclic linkers on P-site binding*. *Bioorg Med Chem Lett*, 2002. 12(21): p. 3089-92.
100. D.E. Levy, M. Bao, D.B. Cherbavaz, J.E. Tomlinson, D.M. Sedlock, C.J. Homcy, and R.M. Scarborough, *Metal coordination-based inhibitors of adenylyl cyclase: novel potent P-site antagonists*. *J Med Chem*, 2003. 46(11): p. 2177-86.
101. A. Haunso, J. Simpson, and F.A. Antoni, *Small ligands modulating the activity of mammalian adenylyl cyclases: a novel mode of inhibition by calmidazolium*. *Mol Pharmacol*, 2003. 63(3): p. 624-31.

102. C. Schlicker, A. Rauch, K.C. Hess, B. Kachholz, L.R. Levin, J. Buck, and C. Steegborn, *Structure-based development of novel adenylyl cyclase inhibitors*. J Med Chem, 2008. 51(15): p. 4456-64.
103. H. Wang, H. Xu, L.J. Wu, S.S. Kim, T. Chen, K. Koga, G. Descalzi, B. Gong, K.I. Vadakkan, X. Zhang, B.K. Kaang, and M. Zhuo, *Identification of an adenylyl cyclase inhibitor for treating neuropathic and inflammatory pain*. Sci Transl Med, 2011. 3(65): p. 65ra3.
104. T. Onda, Y. Hashimoto, M. Nagai, H. Kuramochi, S. Saito, H. Yamazaki, Y. Toya, I. Sakai, C.J. Homcy, K. Nishikawa, and Y. Ishikawa, *Type-specific regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms*. J Biol Chem, 2001. 276(51): p. 47785.
105. K. Iwatsubo, S. Minamisawa, T. Tsunematsu, M. Nakagome, Y. Toya, J.E. Tomlinson, S. Umemura, R.M. Scarborough, D.E. Levy, and Y. Ishikawa, *Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration*. J Biol Chem, 2004. 279(39): p. 40938-45.
106. Y. Toya, C. Schwencke, and Y. Ishikawa, *Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase*. J Mol Cell Cardiol, 1998. 30(1): p. 97-108.
107. C.W. Dessauer, J.J.G. Tesmer, S.R. Sprang, and A.G. Gilman, *Identification of a G_i à binding site on type V adenylyl cyclase*. J Biol Chem, 1998. 273: p. 25831.
108. M. Zhuo, *Neuronal mechanism for neuropathic pain*. Mol Pain, 2007. 3: p. 14.
109. K.C. Hess, B.H. Jones, B. Marquez, Y. Chen, T.S. Ord, M. Kamenetsky, C. Miyamoto, J.H. Zippin, G.S. Kopf, S.S. Suarez, L.R. Levin, C.J. Williams, J. Buck,

- and S.B. Moss, *The "soluble" adenylyl cyclase in sperm mediates multiple signaling events required for fertilization*. *Dev Cell*, 2005. 9(2): p. 249-59.
110. Y. Bai, T. Tsunematsu, Q. Jiao, Y. Ohnuki, Y. Mototani, K. Shiozawa, M. Jin, W. Cai, H.L. Jin, T. Fujita, Y. Ichikawa, K. Suita, R. Kurotani, U. Yokoyama, M. Sato, K. Iwatsubo, Y. Ishikawa, and S. Okumura, *Pharmacological stimulation of type 5 adenylyl cyclase stabilizes heart rate under both microgravity and hypergravity induced by parabolic flight*. *J Pharmacol Sci*, 2012. 119(4): p. 381-9.
111. K. Iwatsubo, C. Bravo, M. Uechi, E. Baljinnyam, T. Nakamura, M. Umemura, L. Lai, S. Gao, L. Yan, X. Zhao, M. Park, H. Qiu, S. Okumura, M. Iwatsubo, D.E. Vatner, S.F. Vatner, and Y. Ishikawa, *Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase*. *Am J Physiol Heart Circ Physiol*, 2012. 302(12): p. H2622-8.
112. G.K. Carnegie, F.D. Smith, G. McConnachie, L.K. Langeberg, and J.D. Scott, *AKAP-Lbc nucleates a protein kinase D activation scaffold*. *Mol Cell*, 2004. 15(6): p. 889-99.
113. K.L. Dodge-Kafka, J. Soughayer, G.C. Pare, J.J. Carlisle Michel, L.K. Langeberg, M.S. Kapiloff, and J.D. Scott, *The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways*. *Nature*, 2005. 437(7058): p. 574-8.
114. G.C. Pare, A.L. Bauman, M. McHenry, J.J. Michel, K.L. Dodge-Kafka, and M.S. Kapiloff, *The mAKAP complex participates in the induction of cardiac myocyte hypertrophy by adrenergic receptor signaling*. *J Cell Sci*, 2005. 118(Pt 23): p. 5637-46.

115. A.L. Bauman, J. Soughayer, B.T. Nguyen, D. Willoughby, G.K. Carnegie, W. Wong, N. Hoshi, L.K. Langeberg, D.M. Cooper, C.W. Dessauer, and J.D. Scott, *Dynamic regulation of cAMP synthesis through anchored PKA-adenylyl cyclase V/VI complexes*. *Mol Cell*, 2006. 23(6): p. 925-31.
116. M.S. Kapiloff, L.A. Piggott, R. Sadana, J. Li, L.A. Heredia, E. Henson, R. Efendiev, and C.W. Dessauer, *An adenylyl cyclase-mAKAPbeta signaling complex regulates cAMP levels in cardiac myocytes*. *J Biol Chem*, 2009. 284(35): p. 23540-6.
117. Y. Yu, B.G. Nair, and T.B. Patel, *Epidermal growth factor stimulates cAMP accumulation in cultured rat cardiac myocytes*. *J Cell Physiol*, 1992. 150(3): p. 559.
118. M. Zaccolo and T. Pozzan, *Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes*. *Science*, 2002. 295(5560): p. 1711-5.
119. V.O. Nikolaev, M. Bunemann, E. Schmitteckert, M.J. Lohse, and S. Engelhardt, *Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling*. *Circ Res*, 2006. 99(10): p. 1084-91.
120. E.J. Neer, D. Echeverria, and S. Knox, *Increase in the size of soluble brain adenylyl cyclase with activation by guanosine 5'-(beta, gamma-imino)triphosphate*. *J Biol Chem*, 1980. 255(20): p. 9782-9.
121. C. Gu, J.J. Cali, and D.M. Cooper, *Dimerization of mammalian adenylyl cyclases*. *Eur J Biochem*, 2002. 269(2): p. 413-21.
122. Q. Ding, R. Gros, J. Chorazyczewski, S.S. Ferguson, and R.D. Feldman, *Isoform-specific regulation of adenylyl cyclase function by disruption of membrane trafficking*. *Mol Pharmacol*, 2005. 67(2): p. 564-71.

123. D.M. Cooper and A.J. Crossthwaite, *Higher-order organization and regulation of adenylyl cyclases*. Trends Pharmacol Sci, 2006. 27(8): p. 426-31.
124. J. Hill, A. Howlett, and C. Klein, *Nitric oxide selectively inhibits adenylyl cyclase isoforms 5 and 6*. Cell Signal, 2000. 12(4): p. 233-7.
125. J. Goldstein, C. Silberstein, and C. Ibarra, *Adenylyl cyclase types I and VI but not II and V are selectively inhibited by nitric oxide*. Braz J Med Biol Res, 2002. 35(2): p. 145-51.
126. R.S. Ostrom, R.A. Bunday, and P.A. Insel, *Nitric oxide inhibition of adenylyl cyclase type 6 activity is dependent upon lipid rafts and caveolin signaling complexes*. J Biol Chem, 2004. 279(19): p. 19846-53.
127. K.A. Fagan, K.E. Smith, and D.M. Cooper, *Regulation of the Ca²⁺-inhibitable adenylyl cyclase type VI by capacitative Ca²⁺ entry requires localization in cholesterol-rich domains*. J Biol Chem, 2000. 275(34): p. 26530.
128. X. Liu, M. Thangavel, S.Q. Sun, J. Kaminsky, P. Mahautmr, J. Stitham, J. Hwa, and R.S. Ostrom, *Adenylyl cyclase type 6 overexpression selectively enhances beta-adrenergic and prostacyclin receptor-mediated inhibition of cardiac fibroblast function because of colocalization in lipid rafts*. Naunyn Schmiedebergs Arch Pharmacol, 2008. 377(4-6): p. 359-69.

Vita

Cameron Servetus Brand was born in Houston, TX. He attended the University of Texas at Dallas, receiving a Bachelor of Science degree in molecular biology in the spring of 2009. The following fall he enrolled at the Graduate School of Biomedical Sciences at the University of Texas Health Science Center in Houston, joining the Cell and Regulatory Biology program.